1 Discovery of rare variants associated with blood pressure regulation through meta-2 analysis of 1.3 million individuals

3

Praveen Surendran^{1,2,3,4,266}, Elena V. Feofanova^{5,266}, Najim Lahrouchi^{6,7,8,266}, Ioanna Ntalla^{9,266}, Savita 4 Karthikeyan^{1,266}, James Cook¹⁰, Lingyan Chen¹, Borbala Mifsud^{9,11}, Chen Yao^{12,13}, Aldi T. Kraja¹⁴, James 5 H. Cartwright⁹, Jacklyn N. Hellwege¹⁵, Ayush Giri^{15,16}, Vinicius Tragante^{17,18}, Gudmar Thorleifsson¹⁸, 6 Dajiang J. Liu¹⁹, Bram P. Prins¹, Isobel D. Stewart²⁰, Claudia P. Cabrera^{9,21}, James M. Eales²², Artur 7 Akbarov²², Paul L. Auer²³, Lawrence F. Bielak²⁴, Joshua C. Bis²⁵, Vickie S. Braithwaite^{20,26,27}, Jennifer A. 8 Brody²⁵, E. Warwick Daw¹⁴, Helen R. Warren^{9,21}, Fotios Drenos^{28,29}, Sune Fallgaard Nielsen³⁰, Jessica D. 9 Faul³¹, Eric B. Fauman³², Cristiano Fava^{33,34}, Teresa Ferreira³⁵, Christopher N. Foley^{1,36}, Nora 10 Franceschini³⁷, He Gao^{38,39}, Olga Giannakopoulou^{9,40}, Franco Giulianini⁴¹, Daniel F. Gudbjartsson^{18,42}, Xiuqing Guo⁴³, Sarah E. Harris^{44,45}, Aki S. Havulinna^{45,46}, Anna Helgadottir¹⁸, Jennifer E. Huffman⁴⁷, Shih-11 12 Jen Hwang^{48,49}, Stavroula Kanoni^{9,50}, Jukka Kontto⁴⁶, Martin G. Larson^{51,52}, Ruifang Li-Gao⁵³, Jaana Lindström⁴⁶, Luca A. Lotta²⁰, Yingchang Lu^{54,55}, Jian'an Luan²⁰, Anubha Mahajan^{56,57}, Giovanni Malerba⁵⁸, 13 14 Nicholas G. D. Masca^{59,60}, Hao Mei⁶¹, Cristina Menni⁶², Dennis O. Mook-Kanamori^{53,63}, David Mosen-15 Ansorena³⁸, Martina Müller-Nurasyid^{64,65,66}, Guillaume Paré⁶⁷, Dirk S. Paul^{1,2,68}, Markus Perola^{46,69}, Alaitz 16 Poveda⁷⁰, Rainer Rauramaa^{71,72}, Melissa Richard⁷³, Tom G. Richardson⁷⁴, Nuno Sepúlveda^{75,76}, Xueling Sim^{77,78}, Albert V. Smith^{79,80,81}, Jennifer A. Smith^{24,31}, James R. Staley^{1,74}, Alena Stanáková⁸², Patrick 17 18 Sulem¹⁸, Sébastien Thériault^{83,84}, Unnur Thorsteinsdottir^{18,80}, Stella Trompet^{85,86}, Tibor V. Varga⁷⁰, Digna R. Velez Edwards⁸⁷, Giovanni Veronesi⁸⁸, Stefan Weiss^{89,90}, Sara M. Willems²⁰, Jie Yao⁹¹, Robin Young^{1,92}, 19 20 Bing Yu⁵, Weihua Zhang^{38,39,93}, Jing-Hua Zhao^{1,20,68}, Wei Zhao⁹⁴, Wei Zhao²⁴, Evangelos Evangelou^{38,95}, 21 Stefanie Aeschbacher⁹⁶, Eralda Asllanaj^{97,98}, Stefan Blankenberg^{90,99,100,101}, Lori L. Bonnycastle¹⁰², Jette Bork-Jensen¹⁰³, Ivan Brandslund^{104,105}, Peter S. Braund^{59,60}, Stephen Burgess^{1,36,68}, Kelly Cho^{106,107,108}, 22 23 Cramer Christensen¹⁰⁹, John Connell¹¹⁰, Renée de Mutsert⁵³, Anna F. Dominiczak¹¹¹, Marcus Dörr^{90,112}, Gudny Eiriksdottir⁷⁹, Aliki-Eleni Farmaki^{113,114}, J. Michael Gaziano^{106,107,108}, Niels Grarup¹⁰³, Megan L. 24 25 Grove-Gaona⁵, Göran Hallmans¹¹⁵, Torben Hansen¹⁰³, Christian T. Have¹⁰³, Gerardo Heiss³⁷, Marit E. 26 Jørgensen¹¹⁶, Pekka Jousilahti⁴⁶, Eero Kajantie^{46,117,118,119}, Mihir Kamat^{1,68}, AnneMari Käräjämäki^{120,121}, 27 Fredrik Karpe^{57,122}, Heikki A. Koistinen^{46,123,124}, Csaba P. Kovesdy¹²⁵, Kari Kuulasmaa⁴⁶, Tiina Laatikainen^{46,126}, Lars Lannfelt¹²⁷, I-Te Lee^{128,129,130,131}, Wen-Jane Lee^{132,133}, LifeLines Cohort Study, Allan 28 29 Linneberg^{134,135}, Lisa W. Martin¹³⁶, Marie Moitry¹³⁷, Girish Nadkarni⁵⁴, Matt J. Neville^{57,122}, Colin N. A. Palmer¹³⁸, George J. Papanicolaou¹³⁹, Oluf Pedersen¹⁰³, James Peters^{1,3,140}, Neil Poulter¹⁴¹, Asif Rasheed¹⁴², 30 31 Katrine L. Rasmussen³⁰, N. William Rayner^{56,57}, Reedik Mägi¹⁴³, Frida Renström^{70,115}, Rainer Rettig^{90,144}, 32 Jacques Rossouw¹⁴⁵, Pamela J. Schreiner¹⁴⁶, Peter J. Sever¹⁴¹, Emil L. Sigurdsson^{147,148}, Tea Skaaby¹⁴⁹, Yan 33 V. Sun¹⁵⁰, Johan Sundstrom¹⁵¹, Gudmundur Thorgeirsson^{18,80,152}, Tõnu Esko^{143,153}, Elisabetta Trabetti⁵⁸, 34 Philip S. Tsao¹⁵⁴, Tiinamaija Tuomi^{155,156,157}, Stephen T. Turner¹⁵⁸, Ioanna Tzoulaki^{38,95,265}, Ilonca 35 Vaartjes^{159,160}, Anne-Claire Vergnaud³⁸, Cristen J. Willer^{161,162,163}, Peter WF. Wilson¹⁶⁴, Daniel R. 36 Witte^{165,166,167}, Ekaterina Yonova-Doing¹, He Zhang¹⁶¹, Naheed Aliya¹⁶⁸, Peter Almgren¹⁶⁹, Philippe Amouyel^{170,171,172,173}, Folkert W. Asselbergs^{17,174,175}, Michael R. Barnes^{9,21}, Alexandra I. Blakemore^{28,176}, 37 38 Michael Boehnke⁷⁷, Michiel L. Bots^{159,160}, Erwin P. Bottinger⁵⁴, Julie E. Buring^{41,177}, John C. Chambers^{38,39,93,178,179}, Yii-Der Ida Chen⁹¹, Rajiv Chowdhury¹, David Conen^{83,180}, Adolfo Correa¹⁸¹, George 39 40 Davey Smith⁷⁴, Rudolf A. de Boer¹⁸², Ian J. Deary^{44,183}, George Dedoussis¹¹³, Panos Deloukas^{9,21,50,184}, Emanuele Di Angelantonio^{1,2,3,68,185,186}, Paul Elliott^{38,39,187,188}, EPIC-CVD, EPIC-InterAct, Stephan B. Felix^{90,112}, Jean Ferrières¹⁸⁹, Ian Ford⁹², Myriam Fornage^{5,73}, Paul W. Franks^{70,190,191,192}, Stephen Franks¹⁹³, 41 42 43 Philippe Frossard¹⁴², Giovanni Gambaro¹⁹⁴, Tom R. Gaunt⁷⁴, Leif Groop^{195,196}, Vilmundur Gudnason^{79,80}, Tamara B. Harris¹⁹⁷, Caroline Hayward⁴⁷, Branwen J. Hennig^{27,198}, Karl-Heinz Herzig^{199,200}, Erik 44 45 Ingelsson^{201,202,203,204}, Jaakko Tuomilehto^{46,205,206,207}, Marjo-Riitta Jarvelin^{28,38,39,208}, J. Wouter Jukema^{86,209}, 46 Sharon L. R. Kardia²⁴, Frank Kee²¹⁰, Jaspal S. Kooner^{39,93,179,211}, Charles Kooperberg²¹², Lenore J. 47 Launer¹⁹⁷, Lars Lind¹⁵¹, Ruth J. F. Loos^{54,213}, Abdulla al Shafi Majumder²¹⁴, Markku Laakso¹²⁶, Mark I. McCarthy^{56,57,122}, Olle Melander³⁴, Karen L. Mohlke²¹⁵, Alison D. Murray²¹⁶, Børge Grønne Nordestgaard³⁰, 48 49 Marju Orho-Melander³⁴, Chris J. Packard²¹⁷, Sandosh Padmanabhan²¹⁸, Walter Palmas²¹⁹, Ozren Polasek²²⁰, David J. Porteous^{221,222}, Andrew M. Prentice^{27,223}, Michael A. Province¹⁴, Caroline L. Relton⁷⁴, Kenneth 50 51 Rice²²⁴, Paul M. Ridker^{41,177}, Olov Rolandsson¹⁹¹, Frits R. Rosendaal⁵³, Jerome I. Rotter²²⁵, Igor Rudan²²⁶, 52

Veikko Salomaa⁴⁶, Nilesh J. Samani^{59,60}, Naveed Sattar¹¹¹, Wayne H.-H. Sheu^{128,129,227,228}, Blair H. Smith²²⁹, 53 Nicole Soranzo^{230,231,232}, Timothy D. Spector⁶², John M. Starr^{44,233}, Sebert Sylvain^{234,235,236}, Kent D. 54 Taylor²³⁷, Timo A. Lakka^{71,72,238}, Nicholas J. Timpson⁷⁴, Martin D. Tobin^{60,239}, Understanding Society 55 Scientific Group, Pim van der Harst^{240,241,242}, Peter van der Meer²⁴², Ramachandran S. Vasan^{51,243}, Niek Verweij²⁴⁴, Jarmo Virtamo⁴⁶, Uwe Völker^{89,90}, David R. Weir³¹, Eleftheria Zeggini^{245,246}, Fadi J. 56 57 Charchar^{59,247,248}, Million Veteran Program, Nicholas J. Wareham²⁰, Claudia Langenberg²⁰, Maciej 58 Tomaszewski^{22,249}, Adam S. Butterworth^{1,2,3,68,185}, Mark J. Caulfield^{9,21}, John Danesh^{1,2,3,68,185,186}, Todd L. 59 Edwards²⁵⁰, Hilma Holm¹⁸, Adriana M. Hung²⁵¹, Cecilia M. Lindgren^{35,252,253}, Chunyu Liu²⁵⁴, Alisa K. 60 Manning^{108,255}, Andrew P. Morris^{10,252,256}, Alanna C. Morrison⁵, Christopher J. O'Donnell²⁵⁷, Bruce M. 61 Psaty^{25,258,259,260}, Danish Saleheen^{1,261,262}, Kari Stefansson^{18,80}, Eric Boerwinkle^{5,263,267}, Daniel I. 62 Chasman^{41,177,267}, Daniel Levy^{51,264,267}, Christopher Newton-Cheh^{6,7,267}, Patricia B. Munroe^{9,21,267} and Joanna 63 M. M. Howson^{1,68,265,267} 64 65 66 67 British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and 68 1. 69 Primary Care, University of Cambridge, Cambridge, UK. British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK. 2. 70 Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, 71 3. 72 Cambridge, UK. Rutherford Fund Fellow, Department of Public Health and Primary Care, University of Cambridge, 73 4. 74 Cambridge, UK. 75 Human Genetics Center, The University of Texas Health Science Center at Houston, Houston, TX, 5. 76 USA. 77 6. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, 78 USA. 79 Cardiovascular Research Center, Center for Genomic Medicine, Massachusetts General Hospital, 7. 80 Boston, MA, USA. Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental 81 8. 82 Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen 83 9. Mary University of London, London, UK. 84 Department of Biostatistics, University of Liverpool, Liverpool, UK. 85 10. College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar. 11. 86 12. Framingham Heart Study, Framingham, MA, USA. 87 Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood 88 13. 89 Institute, National Institutes of Health, Bethesda, MD, USA. Division of Statistical Genomics, Department of Genetics and Center for Genome Sciences and 90 14. Systems Biology, Washington University School of Medicine, St. Louis, MO, USA. 91 Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health, 92 15. Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Tennessee Valley Healthcare System 93 94 (626)/Vanderbilt University, Nashville, TN, USA. Division of Quantitative Sciences, Department of Obstetrics & Gynecology, Vanderbilt Genetics 95 16. 96 Institute, Vanderbilt University Medical Center, Tennessee Valley Healthcare System (626)/Vanderbilt 97 University, Nashville, TN, USA. Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht 98 17. 99 University, Utrecht, The Netherlands. 100 18. deCODE genetics/Amgen, Inc., Reykjavik, Iceland. 19. Institute of Personalized Medicine, Penn State College of Medicine, Hershey, PA, USA. 101 102 20. MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK. 2

21. National Institute for Health Research Barts Cardiovascular Biomedical Research Centre, Queen 103 Mary University of London, London, UK. 104 Division of Cardiovascular Sciences, Faculty of Medicine, Biology and Health, University of 105 22. 106 Manchester, Manchester, UK. 107 Joseph J. Zilber School of Public Health, University of Wisconsin, Milwaukee, WI, USA. 23. 108 24. Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, 109 25. 110 WA, USA. MRC Nutrition and Bone Health Group, University of Cambridge, Cambridge, UK. Formerly, MRC 111 26. Human Nutrition Research, Cambridge, UK. 112 MRC Unit The Gambia at London School of Hygiene & Tropical Medicine, Banjul, The Gambia. 113 27. 114 28. Department of Life Sciences, College of Health and Life Sciences, Brunel University London, 115 London, UK. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College 116 29. 117 London, London, UK. Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University 118 30. Hospital, Herley, Denmark. 119 Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, 120 31. USA. 121 Internal Medicine Research Unit, Pfizer, Cambridge MA, USA. 122 32. Department of Medicine, University of Verona, Verona, Italy. 33. 123 Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden. 34. 124 The Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of 125 35. 126 Oxford, Oxford, UK. MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. 36. 127 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, 128 37. 129 Chapel Hill, NC, USA. Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of 130 38. Public Health, Imperial College London, London, UK. 131 National Institute for Health Research (NIHR) Imperial Biomedical Research Centre, Imperial 132 39. College London, London, UK. 133 Centre for Genomic Health, Queen Mary University of London, London, UK. 134 40. 41. Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA. 135 School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland. 136 42. 137 43. The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, LABioMed at Harbor-UCLA Medical Center, Torrance, CA, USA. 138 Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK. 139 44. Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK. 140 45. Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland. 46. 141 MRC Human Genetics Unit, IGMM, University of Edinburgh, Western General Hospital, 142 47. 143 Edinburgh, UK. Population Sciences, Branch, National Heart, Lung, and Blood Institute, National Institute of Health, 48. 144 145 Bethesda, MD, USA. Boston University's and Boston University's and National Heart, Lung and Blood Institute's 146 49. Framingham Heart Study, Framingham, MA, USA. 147 Centre for Genomic Health, Life Sciences, Queen Mary University of London, London, UK. 148 50. Boston University's and National Heart, Lung and Blood Institute's Framingham Heart Study, 149 51. Framingham, MA, USA. 150 Biostatistics Department, Boston University School of Public Health, Boston, MA, USA. 151 52.

152 153	53. 54.	Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. The Charles Bronfman Institute for Personalized Medicine at Mount Sinai, Icahn School of Medicine
154		unt Sinai, New York, NY, USA.
155 156	55. Epidei	Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt miology Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
157	56.	Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford,
158	Oxfor	d, UK.
159	57.	Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine,
160		rsity of Oxford, Oxford, UK.
161	58.	Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona,
162	Italy.	
163	59.	Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
164	60.	National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK.
165	61.	Department of Data Science, School of Population Health, University of Mississippi Medical Center,
166		on, MS, USA.
167	62.	Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
168	63. Nether	Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The
169 170	64.	
170		Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for onmental Health, Neuherberg, Germany.
172	65.	Department of Medicine I, Ludwig-Maximilians-University Munich, Munich, Germany.
173	66.	Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Germany.
174	67.	Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario,
174	Canad	
176	68.	National Institute for Health Research Cambridge Biomedical Research Centre, University of
177		ridge and Cambridge University Hospitals, Cambridge, UK.
178	69.	Clinical and Molecular Metabolism Research Program (CAMM), Faculty of Medicine, University of
179	Helsin	ki, Helsinki, Finland.
180	70.	Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Skåne
181	Unive	rsity Hospital Malmö, Malmö, Sweden.
182	71.	Kuopio Research Institute of Exercise Medicine, Kuopio, Finland.
183	72.	Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio,
184	Finlan	
185	73.	Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health
186		ce Center at Houston, Houston, TX, USA.
187	74.	MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School,
188		rsity of Bristol, Bristol, UK.
189 190	75. Hygie	Department of Infection Biology, Faculty of Tropical and Infectious Diseases, London School of ne & Tropical Medicine, London, UK.
191	76.	Centre of Statistics and Applications of University of Lisbon, Lisbon, Portugal, Lisbon.
192	70. 77.	Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor,
193	MI, U	
194	78.	Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
195	79.	Icelandic Heart Association, Kopavogur, Iceland.
196	80.	Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
197	81.	Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
198	82.	University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
199	83.	Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
		-

Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University, Quebec 84. 200 City, Quebec, Canada. 201 Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The 85. 202 203 Netherlands. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. 204 86. 205 87. Vanderbilt Genetics Institute, Vanderbilt Epidemiology Center, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center; Tennessee Valley Health Systems VA, Nashville, TN, 206 207 USA. Research Center in Epidemiology and Preventive Medicine, Department of Medicine and Surgery, 208 88. 209 University of Insubria, Varese, Italy. Interfaculty Institute for Genetics and Functional Genomics, University Medicine and University of 210 89. Greifswald, Greifswald, Germany. 211 DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Greifswald, Germany. 212 90. 213 91. The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, LABioMed at Harbor-UCLA Medical Center, Torrance, CA, USA. 214 Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK. 215 92. 216 93. Department of Cardiology, Ealing Hospital, Middlesex, UK. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA. 217 94. Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, 218 95. 219 Greece. Division of Cardiology, University Hospital, Basel, Switzerland. 220 96. Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. 97. 221 222 98. Department of Epidemiology, Erasmus MC, University Medical Centre, Rotterdam, The 223 Netherlands. Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, 224 99. 225 Germany. University Medical Center Hamburg Eppendorf, Hamburg, Germany. 226 100. German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Hamburg, 227 101. 228 Germany. Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, 229 102. 230 NIH, Bethesda, MD, USA. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical 231 103. Sciences, University of Copenhagen, Copenhagen, Denmark. 232 Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark. 233 104. Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark. 234 105. Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston 235 106. care System, Boston, MA, USA. 236 Health Division of Aging, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 237 107. 238 108. Department of Medicine, Harvard Medical School, Boston, MA, USA. 239 109. Medical department, Lillebaelt Hospital, Vejle, Denmark. 240 110. University of Dundee, Ninewells Hospital & Medical School, Dundee, UK. Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, 241 111. 242 University of Glasgow, Glasgow, UK. Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany. 243 112. Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio 244 113. 245 University, Athens, Greece. Department of Population Science and Experimental Medicine, Institute of Cardiovascular Science, 246 114. 247 University College London, London, UK. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. 248 115.

Steno Diabetes Center, Copenhagen, Gentofte, Denmark. 249 116. PEDEGO Research Unit, MRC Oulu, Oulu University Hospital and University of Oulu, Finland. 250 117. Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 118. 251 252 Trondheim, Norway. Hospital for Children and Adolescents, Helsinki University Central Hospital and University of 253 119. 254 Helsinki, Helsinki, Finland. Department of Primary Health Care, Vaasa Central Hospital, Vaasa, Finland. 255 120. Diabetes Center, Vaasa Health Care Center, Vaasa, Finland. 256 121. Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, UK. 257 122. Department of Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, 258 123. 259 Finland. Minerva Foundation Institute for Medical Research, Helsinki, Finland. 124. 260 Nephrology Section, Memphis VA Medical Center, Memphis, TN, USA. 261 125. 262 126. Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, 263 Finland. Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden. 264 127. 265 128. Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans 266 General Hospital, Taichung, Taiwan. School of Medicine, National Yang-Ming University, Taipei, Taiwan. 267 129. 268 130. School of Medicine, Chung Shan Medical University, Taichung, Taiwan. College of Science, Tunghai University, Taichung, Taiwan. 269 131. Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan. 270 132. Department of Social Work, Tunghai University, Taichung, Taiwan. 271 133. Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, The Capital 272 134. 273 Region, Copenhagen, Denmark. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of 274 135. 275 Copenhagen, Copenhagen, Denmark. George Washington University School of Medicine and Health Sciences, Washington DC, USA. 276 136. Department of Public health, Strasbourg University hospital, University of Strasbourg, Strasbourg, 277 137. France. 278 Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, 279 138. 280UK. Epidemiology Branch, NHLBI, Bethesda, MD, USA. 281 139. Department of Immunology and Inflammation, Imperial College London, London, UK. 282 140. International Centre for Circulatory Health, Imperial College London, London, UK. 283 141. 284 Centre for Non-Communicable Diseases, Karachi, Pakistan. 142. 285 Institute of Genomics, University of Tartu, Tartu, Estonia. 143. 286 144. Institute of Physiology, University Medicine Greifswald, Karlsburg, Germany. 145. Division of Cardiovascular Sciences, NHLBI, Bethesda, MD, USA. 287 Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, 288 146. 289 USA. Department of Family Medicine, University of Iceland, Reykjavik, Iceland. 290 147. Development Centre for Primary Health Care in Iceland, Iceland. 291 148. Center for Clinical Research and Disease Prevention, Bispebjerg and Frederiksberg Hospital, The 292 149. Capital Region, Copenhagen, Denmark. 293 Department of Epidemiology, Emory University Rollins School of Public Health; Department of 294 150. 295 Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA. Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 296 151.

- 152. Department of Internal Medicine, Division of Cardiology, Landspitali The National University
 Hospital of Iceland, Reykjavik, Iceland.
- 299 153. Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.
- 300 154. VA Palo Alto Health Care System, Division of Cardiovascular Medicine, Stanford University School
- 301 of Medicine, Stanford, CA, USA.
- 302 155. Folkhälsan Research Centre, Helsinki, Finland.
- 303 156. Department of Endocrinology, Helsinki University Central Hospital, Helsinki, Finland.
- 304 157. Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre,
- 305 Malmö, Sweden. Institute for Molecular Medicine Helsinki (FIMM), Helsinki University, Helsinki, Finland.
- 306 158. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University
 of Utrecht, University of Utrecht, The Netherlands.
- 160. Center for Circulatory Health, University Medical Center Utrecht, University of Utrecht, TheNetherlands.
- 161. Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan,
 Ann Arbor, MI, USA.
- 162. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor,MI, USA.
- 163. Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA.
- 316 164. Atlanta VAMC and Emory Clinical Cardiovascular Research Institute, Atlanta, GA, USA.
- 317 165. Department of Public Health, Aarhus University, Aarhus, Denmark.
- 318 166. Danish Diabetes Academy, Odense, Denmark.
- 319 167. Steno Diabetes Center Aarhus, Aarhus, Denmark.
- 168. International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Mohakhali, Dhaka,Bangladesh.
- 322 169. Dep of Medicine, Lund University, Malmö, Sweden.
- 170. Univ. Lille, U1167 RID-AGE Facteurs de risque et déterminants moléculaires des maladies liées
 au vieillissement, Lille, France.
- 325 171. Inserm, U1167, Lille, France.
- 326 172. CHU Lille, U1167, Lille, France.
- 173. Institut Pasteur de Lille, U1167, Lille, France.
- 174. Health Data Research UK, Institute of Health Informatics, University College London, London, UK.
- 175. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College
 London, London, UK.
- 331 176. Section of Investigative Medicine, Imperial College London, Hammersmith Hospital Campus,
- London, UK.
- 333 177. Harvard Medical School, Boston, MA, USA.
- 178. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
- 335 179. Imperial College Healthcare NHS Trust, London, UK.
- 180. Cardiovascular Research Institute Basel, Basel, Switzerland.
- 181. Jackson Heart Study, Department of Medicine, University of Mississippi Medical Center, Jackson,
 MS, USA.
- 182. University of Groningen, University Medical Center Groningen, Department of Cardiology,
- Groningen, The Netherlands.
- 183. Department of Psychology, University of Edinburgh, Edinburgh, UK.
- 342 184. Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-
- 343 HD), King Abdulaziz University, Jeddah, Saudi Arabia.
- 185. National Institute for Health Research Blood and Transplant Research Unit in Donor Health and
- Genomics, University of Cambridge, Cambridge, UK.

Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK. 346 186. Health Data Research UK – London at Imperial College London, London, UK. 347 187. UKDRI, Dementia Research Institute at Imperial College London, London, UK. 348 188. Department of Cardiology and Department of Epidemiology, INSERM UMR 1027, Toulouse 349 189. 350 University Hospital, Toulouse, France. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 190. 351 Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden. 352 191. Oxford Center for Diabetes, Endocrinology & Metabolism, Radcliff Department of Medicine, 353 192. University of Oxford, Oxford, UK. 354 Institute of Reproductive & Developmental Biology, Imperial College London, London, UK. 355 193. Division of Nephrology, Department of Medicine, University of Verona, Verona, Italy. 356 194. Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, 357 195. 358 Malmö, Sweden. Institute for Molecular Medicine Helsinki (FIMM), Helsinki University, Helsinki, Finland. 359 196. Laboratory of Epidemiology and Population Sciences, National Institute of Aging, Bethesda, MD, 360 197. 361 USA. 362 198. Wellcome Trust, London, UK. 199. Institute of Biomedicine, Medical Research Center (MRC), University of Oulu, and University 363 364 Hospital Oulu, Oulu, Finland. Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan, 365 200. Poland. 366 Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of 367 201. 368 Medicine, Stanford, CA, USA. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala 369 202. 370 University, Uppsala, Sweden. Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA. 371 203. Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA. 372 204. Department of Public Health, University of Helsinki, Helsinki, Finland. 373 205. 374 206. Saudi Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia. National Institute of Public Health, Madrid, Spain. 375 207. Unit of Primary Care, Oulu University Hospital, Oulu, Finland. 376 208. Netherlands Heart Institute, Utrecht, The Netherlands, Utrecht, The Netherlands. 377 209. Centre for Public Health, Queens University Belfast, Belfast, UK. 378 210. 379 National Heart and Lung Institute, Imperial College London, London, UK. 211. 380 212. Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, WA, USA. 381 The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, 213. 382 New York, NY, USA. National Institute of Cardiovascular Diseases, Sher-e-Bangla Nagar, Dhaka, Bangladesh. 383 214. 384 Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. 215. The Institute of Medical Sciences, Aberdeen Biomedical Imaging Centre, University of Aberdeen, 385 216. 386 Aberdeen, UK. University of Glasgow, Glasgow, UK. 387 217. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. 388 218. Department of Medicine, Columbia University Medical Center, New York, NY, USA. 389 219. Department of Public Health, University of Split School of Medicine, Split, Croatia. 390 220. Centre for Genomic and Experimental Medicine, Institute of Genetics & Molecular Medicine, 391 221. 392 University of Edinburgh, Western General Hospital, Edinburgh, UK. Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, The 393 222. 394 University of Edinburgh, Edinburgh, UK. 8

- 395 223. MRC International Nutrition Group at London School of Hygiene & Tropical Medicine, London,
 396 UK.
- 397 224. Department of Biostatistics, University of Washington, Seattle, WA, USA.
- 398 225. Institute for Translational Genomics and Population Sciences, Departments of Pediatrics and
- 399 Medicine, LABioMed at Harbor-UCLA Medical Center, Torrance, CA, USA.
- 226. Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics,
 University of Edinburgh, Edinburgh, UK.
- 402 227. School of Medicine, National Defense Medical Center, Taipei, Taiwan.
- 403 228. Institute of Medical Technology, National Chung-Hsing University, Taichung, Taiwan.
- 229. Division of Population Health and Genomics, Ninewells Hospital and Medical School, University of
 Dundee, Dundee, UK.
- 230. Department of Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton,Cambridge, UK.
- 408 231. Department of Haematology, University of Cambridge, Cambridge, UK.
- 409 232. The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor
- Health and Genomics at the University of Cambridge, Cambridge, UK.
- 411 233. Alzheimer Scotland Research Centre, University of Edinburgh, Edinburgh, UK.
- 412 234. Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland.
- 413 235. Biocenter Oulu, University of Oulu, Oulu, Finland.
- 236. Department of Genomics of Complex Diseases, School of Public Health, Imperial College London,London, UK.
- 237. Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research
 Institute at Harbor/UCLA Medical Center, Torrance, CA, USA.
- 418 238. Institute of Biomedicine/Physiology, University of Eastern Finland, Kuopio Campus, Kuopio,
 419 Finland.
- 420 239. Department of Health Sciences, University of Leicester, Leicester, UK.
- 421 240. University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen,422 The Netherlands.
- 423 241. Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The424 Netherlands.
- 425 242. University of Groningen, University Medical Center Groningen, Department of Cardiology,426 Groningen, The Netherlands.
- 427 243. Boston University Schools of Medicine and Public Health, Boston, MA, USA.
- 428 244. University Medical Center Groningen, Groningen, The Netherlands.
- 429 245. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
- 430 246. Institute of Translational Genomics, Helmholtz Zentrum München German Research Center for
- 431 Environmental Health, Neuherberg, Germany.
- 432 247. School of Health and Life Sciences, Federation University Australia, Ballarat, Victoria, Australia.
- 433 248. Department of Physiology, University of Melbourne, Melbourne, Victoria, Australia.
- 249. Division of Medicine, Manchester University NHS Foundation Trust, Manchester Academic Health
 Science Centre, Manchester, UK.
- 436 250. Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health,
- Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Tennessee Valley Healthcare System
 (626)/Vanderbilt University, Nashville, TN, USA.
- 439 251. VA Tennessee Valley Healthcare System, Division of Nephrology & Hypertension, Department of

Medicine, Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, TN,
USA.

442 252. Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

- 443 253. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA,
 444 USA.
- 445 254. Boston University School of Public Health, Boston, MA, USA.
- 446 255. Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA.
- 256. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester,Manchester, UK.
- 449 257. VA Boston Healthcare, Section of Cardiology and Department of Medicine, Brigham and Women's
 450 Hospital, Harvard Medical School, Boston, MA, USA.
- 451 258. Department of Epidemiology, University of Washington, Seattle, WA, USA.
- 452 259. Department of Health Services, University of Washington, Seattle, WA, USA.
- 453 260. Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
- 454 261. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of
- 455 Pennsylvania, Philadelphia, PA, USA.
- 456 262. Center for Non-Communicable Diseases, Karachi, Pakistan.
- 457 263. Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
- 264. Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institute of Health,
 Bethesda, MD, USA.
- 460 265. Department of Genetics, Novo Nordisk Research Centre Oxford, Oxford, UK.
- 461
- 462 *Current address (if different to the affiliations)
- 463 Mark McCarthy: Genentech, South San Francisco, CA, USA.
- 464
- 465 266. These authors contributed equally to this work.
- 466 267. These authors jointly supervised the work.
- 467
- 468 Corresponding authors:
- 469 Joanna M. M. Howson: JMMHowson@gmail.com
- 470 Patricia B. Munroe: P.B.Munroe@qmul.ac.uk
- 471
- 472

Genetic studies of blood pressure (BP) to date have mainly analyzed common variants (minor allele frequency, MAF > 0.05). In a meta-analysis of up to >1.3 million participants, we discovered 106 new BP-associated genomic regions and 87 rare (MAF \leq 0.01) variant BP associations ($P < 5 \times 10^{-8}$), of which 32 were in new BP-associated loci and 55 were independent BP-associated SNVs within known BP-associated regions. Average effects of rare variants (44% coding) were ~8 times larger than common variant effects and indicate potential candidate causal genes at new and known loci (e.g. GATA5, PLCB3). BP-associated variants (including rare and common) were enriched in regions of active chromatin in fetal tissues, potentially linking fetal development with BP regulation in later life. Multivariable Mendelian randomization suggested possible inverse effects of elevated systolic and diastolic BP on large artery stroke. Our study demonstrates the utility of rare variant analyses for identifying candidate genes and the results highlight potential therapeutic targets.

489	Increased blood pressure (BP) is a major risk factor for cardiovascular disease (CVD) and related disability
490	worldwide ¹ . Its complications are estimated to account for ~ 10.7 million premature deaths annually ¹ .
491	Genome-wide association studies (GWAS) and exome array-wide association studies (EAWAS) have
492	identified over 1,000 BP-associated single nucleotide variants (SNVs) ²⁻¹⁹ for this complex, heritable,
493	polygenic trait. The majority of these are common SNVs (MAF > 0.05) with small effects on BP. Most
494	reported associations involve non-coding SNVs, and due to linkage disequilibrium (LD) between common
495	variants, these studies provide limited insights into the specific causal genes through which their effects are
496	mediated. The exome array was designed to facilitate analyses of rare coding variants (MAF \leq 0.01) with
497	potential functional consequences. Over 80% of SNVs on the array are rare, \sim 6% are low frequency (0.01 <
498	MAF \leq 0.05), and ~80% are missense, <i>i.e.</i> the variants implicate a candidate causal gene through changes to
499	the amino acid sequence. Previously, using the exome array, we identified four BP loci with rare variant
500	associations (<i>RBM47</i> , <i>COL21A1</i> , <i>RRAS</i> , <i>DBH</i>) ^{13,14} and a rare nonsense BP variant in <i>ENPEP</i> , encoding an
501	aminopeptidase with a known role in BP regulation ¹³ . These findings confirmed the utility of rare variant
502	studies for identifying potential causal genes. These rare variant associations had larger effects on BP
503	(typically \sim 1.5 mmHg per minor allele) than common variants identified by previous studies (typically \sim 0.5
504	mmHg per minor allele), many of which had power to detect common variants with large effects. Here, we
505	combine the studies from our previous two exome array reports with additional studies, including the UK
506	Biobank (UKBB) study, to analyze up to ~1.319 million participants and investigate the role of rare SNVs in
507	BP regulation.

511 Results

512 We performed an EAWAS and a rare variant GWAS (RV-GWAS) of imputed and genotyped SNVs to

identify variants associated with BP traits, hypertension (HTN), and inverse normal transformed systolic BP
(SBP), diastolic BP (DBP), and pulse pressure (PP) using (i) single variant analysis and (ii) a gene-based test

approach. An overview of our study design for both the EAWAS and for the RV-GWAS is provided inFigure 1.

517

Blood pressure associations in the EAWAS. We performed a discovery meta-analysis to identify genetic 518 variants associated with BP in up to ~1.32 million individuals. To achieve this, we first performed a meta-519 analysis of 247,315 exome array variants in up to 92 studies (870,217 participants, including UKBB) for 520 association with BP. Stage 1 (Fig. 1, Methods, and Supplementary Information). There were 362 BP loci 521 known at the time of the analysis (Supplementary Table 1), 240 of which were covered on the exome array. 522 To improve statistical power for discovery for a subset of variants significant in Stage 1 at $P < 5 \times 10^{-8}$ 523 outside of the known BP regions (Supplementary Table 1a), we requested summary association statistics 524 from three additional studies (Million Veteran Program (MVP), deCODE, and GENOA). We then 525 performed meta-analyses of the three data request studies and Stage 1 results to discover novel variants 526 associated with BP. In total, 343 SNVs (200 genomic regions; Methods) were associated ($P < 5 \times 10^{-8}$) with 527 one or more BP traits in the Stage 2 single variant European (EUR) EAWAS meta-analyses involving up to 528 ~1.168 million individuals (Table 1, Fig. 2, Supplementary Table 2, and Supplementary Information). A 529 further seven SNVs (seven genomic regions) were only associated ($P < 5 \times 10^{-8}$) in the pan-ancestry (PA) 530 meta-analyses of ~1.319 million individuals (Supplementary Table 2). All 350 SNV-BP associations were 531 novel at the time of analysis (204 loci), 220 have subsequently been reported^{20,21}, and 130 SNVs (99 loci) 532 remain novel, including nine rare and 13 low-frequency SNVs (Fig. 2, Supplementary Table 2, 533 Supplementary Fig. 1). 534

All nine novel rare BP-associated SNVs identified in the EAWAS were conditionally independent of common variant associations within the respective regions (Supplementary Table 3) using the multi-SNPbased conditional and joint association analysis (GCTA v1.91.4)²² with the Stage 1 EUR EAWAS results

- 538 (Methods and Supplementary Table 4). In addition to the rare variants, there were 147 additional distinct (*P*
- $< 1 \times 10^{-6}$) common SNV-BP associations (46% were missense variants), and 18 distinct low-frequency
- 540 SNVs (89% were missense). Approximately 59% of the distinct BP-associated SNVs were coding or in
- strong LD ($r^2 > 0.8$) with coding SNVs. In total, 42 of the 99 novel loci had two or more distinct BP-
- associated SNVs in the conditional analyses. Of the 50 loci that were previously identified using UKBB^{16,17}
- and were on the exome array, 43 replicated at P < 0.001 (Bonferroni correction for 50 known variants) in
- samples independent of the original discovery (Supplementary Table 5).
- 545

Blood pressure associations from EUR RV-GWAS. We tested a further 29,454,346 (29,404,959 imputed 546 and 49,387 genotyped) rare SNVs for association with BP in 445,360 UKBB participants²³ using BOLT-547 LMM²⁴ (Fig. 1 and Methods). The SNVs analyzed as part of the EAWAS were not included in the RV-548 GWAS. Similar to EAWAS, within RV-GWAS we performed a single discovery meta-analyses to identify 549 rare SNVs associated with BP. In Stage 1 (UKBB), 84 rare SNVs outside of the known BP loci (at the time 550 of our analyses) were associated with one or more BP traits at $P < 1 \times 10^{-7}$ (Supplementary Table 6). 551 Additional data were requested from MVP for the 84 BP-associated SNVs in up to 225,112 EUR from the 552 MVP, and 66 were available. Meta-analyses of Stage 1 (UKBB) and results obtained from MVP were 553 performed for novel rare variant discovery. We identified 23 unique rare SNVs associated with one or more 554 BP traits ($P < 5 \times 10^{-8}$) with consistent direction of effects in a meta-analysis of UKBB and MVP (min 555 $P_{\text{heterogeneity}} = 0.02$) (Table 1, Fig. 2, Supplementary Table 7, and Supplementary Fig. 1). Two of the SNVs, 556 rs55833332 (p.Arg35Gly) in NEK7 and rs200383755 (p.Ser19Trp) in GATA5, were missense. Eleven rare 557 SNVs were genome-wide significant in UKBB alone but were not available in MVP and await further 558 support in independent studies (Supplementary Table 7). 559 560

Rare and low frequency variant associations at established BP loci. It is difficult to prioritize candidate genes at common variant loci for functional follow up. We believe analysis of rare (MAF < 0.01) and very low frequency coding variants (MAF \leq 0.02) in known loci may provide further support for or identify a candidate causal gene at a locus. Twelve of the 240 BP-associated regions had one or more conditionally

565	independent rare variant associations ($P < 10^{-6}$ in the GCTA joint model of the EUR Stage 1 EAWAS;
566	Methods, Table 2, and Supplementary Table 3). A further nine loci had one or more conditionally
567	independent BP-associated SNVs with MAF \leq 0.02 (Table 2 and Supplementary Table 8). In total, 183
568	SNVs (rare and common) across 110 known loci were not identified previously.
569	We used FINEMAP ²⁵ to fine-map 315 loci known at the time of our analysis and available in UKBB
570	GWAS, which provides dense coverage of genomic variation not available on the exome array. Of these, 36
571	loci had one or more conditionally independent rare variant associations (Supplementary Table 8), and 251
572	loci had multiple common variants associations. We also replicated rare variant associations that we
573	reported previously ^{13,14} at <i>RBM47</i> , <i>COL21A1</i> , <i>RRAS</i> , and <i>DBH</i> ($P < 5 \times 10^{-5}$) in UKBB (independent of
574	prior studies). Overall, from both FINEMAP and GCTA, we identified 40 loci with one or more rare SNV
575	associations, independent of previously reported common variant associations (Table 3, Fig. 2,
576	Supplementary Table 8, and Supplementary Information).
577	We note that, of 256 known variants identified without UKBB participants (Supplementary Table
578	1a), 229 replicated at $P < 1.95 \times 10^{-4}$ (Bonferroni adjusted for 256 variants) in UKBB.
579	
580	Gene-based tests to identify BP-associated genes. To test whether rare variants in aggregate affect BP
581	regulation, we performed gene-based tests for SBP, DBP, and PP using SKAT ²⁶
582	(<u>https://genome.sph.umich.edu/wiki/RareMETALS</u>), including SNVs with MAF ≤ 0.01 that were predicted
583	by VEP ²⁷ to have high or moderate impact (Methods). We performed separate analyses within the Stage 1
584	EAWAS and the UKBB RV-GWAS. Six genes in the EAWAS (FASTKD2, CPXM2, CENPJ, CDC42EP4,
585	OTOP2, SCARF2) and two in the RV-GWAS (FRY, CENPJ) were associated with BP ($P < 2.5 \times 10^{-6}$,
586	Bonferroni adjusted for ~20,000 genes) and were outside known and new BP loci (Supplementary Tables 1
587	and 9). To ensure these associations were not attributable to a single (sub-genome-wide significant) rare
588	variant, we also performed SKAT tests conditioning on the variant with the smallest P-value in the gene
589	(Methods and Supplementary Table 9). <i>FRY</i> had the smallest conditional <i>P</i> -value ($P = 0.0004$), but did not
589 590	(Methods and Supplementary Table 9). <i>FRY</i> had the smallest conditional <i>P</i> -value ($P = 0.0004$), but did not pass our pre-determined conditional significance threshold (conditional SKAT $P \le 0.0001$; Methods),


- suggesting that all gene associations are due to single (sub-genome-wide significant) rare variants and not
- 592 due to the aggregation of multiple rare variants.

593 Amongst the known loci, five genes (*NPR1*, *DBH*, *COL21A1*, *NOX4*, *GEM*) were associated with BP 594 due to multiple rare SNVs independent of the known common variant associations (conditional $P \le 1 \times 10^{-5}$; 595 Methods, Supplementary Information, and Supplementary Table 9) confirming the findings in the single 596 variant conditional analyses above (Supplementary Table 8).

597 We also performed gene-based tests using a MAF \leq 0.05 threshold to assess sensitivity to the MAF \leq 598 0.01 threshold. The results were concordant with the MAF \leq 0.01 threshold findings, and two new genes 599 (*PLCB3* and *CEP120*) were associated with BP due to multiple SNVs and were robust to conditioning on 600 the top SNV in each gene (Supplementary Information and Supplementary Table 9).

601

Rare variant BP associations. In total, across the EAWAS and the RV-GWAS, there were 32 new BP-602 associated rare variants spanning 18 new loci (Table 1 and Fig. 2). Of these 32, five (representing five loci) 603 were genome-wide significant for HTN, 22 (ten loci) for SBP, 14 (six loci) for DBP, and 15 (ten loci) for PP 604 (Supplementary Tables 1, 2, 3, 6, and 7). Ten of the new rare variants were missense. Within previously 605 reported loci, there were 55 independent rare-variant associations (representing 40 loci) from either the 606 607 EAWAS or RV-GWAS, making a total of 87 independent rare BP-associated SNVs. We identified 45 BPassociated genes, eight of which were due to multiple rare variants and independent of common variant 608 associations ($P < 1 \times 10^{-4}$, Methods). Twenty-one rare variants were located within regulatory elements (e.g. 609 enhancers), highlighting genetic influence on BP levels through gene expression (Fig. 2). The rare variants 610 contributed to BP variance explained (Supplementary Information). 611



- compared to common (mean effect ~0.135 SD/minor allele for rare SNVs, ~0.04 SD/minor allele for lowfrequency and ~0.016 SD/minor allele for common SNVs). Our study was exceptionally well-powered to detect common variants (MAF > 0.05) with similarly large effects but found none, consistent with earlier BP GWAS and genetic studies of some other common complex traits^{28,29,36}.
- 622
- 623 **Overlap of rare BP associations with monogenic BP genes.** Twenty-four genes are reported in ClinVar to 624 cause monogenic conditions with hypertension or hypotension as a primary phenotype. Of these, three 625 (NR3C2, AGT, PDE3A) were associated with BP in SKAT tests in the EAWAS (P < 0.002, Bonferroni 626 adjusted for 24 tests; Supplementary Table 10). These genes also had genome-wide significant SNV-BP 627 associations in the EAWAS and/or RV-GWAS (Supplementary Table 10).
- 628

Functional annotation of rare BP-associated SNVs. None of the BP-associated rare SNVs (from known 629 or novel loci) had been previously reported as expression quantitative trait loci (eQTL) in any tissue ($P > 5 \times$ 630 10⁻⁸; Supplementary Table 11 and Methods). We used GTEx v7 data to examine in which tissues the genes 631 closest to the rare BP-SNVs were expressed (Extended Data Fig. 2 and Supplementary Table 4). Many of 632 the eQTL gene transcripts were expressed in BP-relevant tissues (e.g. kidney, heart, and arteries). We 633 observed significant enrichment (Bonferroni adjusted P < 0.05) in liver, kidney, heart left ventricle, 634 pancreas, and brain tissues, where the BP genes were down-regulated. In contrast, the BP genes were up-635 regulated in tibial artery, coronary artery, and aorta (Extended Data Fig. 3). There were 33 genes at 30 636 known loci with novel BP rare variants (from Supplementary Table 12); distinct known common BP 637 variants at these known loci were eQTLs for 52% of these genes, providing additional evidence that the rare 638 variants implicate plausible candidate genes (Supplementary Table 12). 639 We tested whether genes near rare BP-associated SNVs were enriched in gene sets from Gene 640 Ontology (GO), KEGG, Mouse Genome Informatics (MGI), and Orphanet (Methods and Supplementary 641 642 Table 4). These (rare variant) genes from both known and novel loci were enriched in BP-related pathways

(Bonferroni adjusted P < 0.05; Methods and Supplementary Table 13), including "regulation of blood vessel

644 size" (GO) and "renin secretion" (KEGG). Genes implicated by rare SNVs at known loci were enriched in

645 "tissue remodeling" and "artery aorta" (GO). Genes implicated by rare SNVs at new BP-loci were enriched

646 in rare circulatory system diseases (that include hypertension and rare renal diseases) in Orphanet.

647

Potential therapeutic insights from the rare BP-associated SNVs. Twenty-three of the genes near rare or 648 low-frequency BP-associated variants in novel and known loci were potentially druggable as suggested by 649 the "druggable genome"³⁰ (Supplementary Information and Supplementary Tables 4 and 14). Six genes 650 (four with rare variants) are already drug targets for CVD conditions, while 15 others are in development or 651 used for other conditions. As an example, the renin-angiotensin-aldosterone system (RAAS) is one of 652 the principal homeostatic mechanisms for BP control, and aldosterone is the main mineralocorticoid 653 (secreted by adrenal glands) and binds receptors, including NR3C2, resulting in sodium retention by 654 the kidney and increased potassium excretion. Spironolactone is an aldosterone antagonist widely used in 655 heart failure and as a potassium-sparing anti-hypertensive medication that targets NR3C2 (Open targets: 656 https://www.opentargets.org). 657

658

659 **Overlap of new BP-associations with metabolites.** To identify novel BP variants that are metabolite QTLs, 660 we performed *in silico* lookups of new sentinel and conditionally independent BP variants for association 661 with 913 plasma metabolites measured using the Metabolon HD4 platform in ~14,000 individuals (Methods 662 and Supplementary Table 4). Nine BP-associated variants were associated with 25 metabolites ($P < 5 \times 10^{-8}$) 663 involved in carbohydrate, lipids, cofactors and vitamins, nucleotide (cysteine), and amino acid metabolism 664 (Supplementary Table 15), while 11 were unknown.

We performed MR analyses to assess the influence of the 14 known metabolites (Supplementary Table 15) on BP. Lower levels of 3-methylglutarylcarnitine(2) (acyl carnitines involved in long-chain fatty acid metabolism in mitochondria and in leucine metabolism) were significantly associated with increased DBP (P < 0.003, 0.05/14 metabolites; Supplementary Table 16). There was no suggestion of reverse causation, i.e. BP did not affect 3-methylglutarylcarnitine(2) (P > 0.04; Supplementary Table 16). We further tested whether the association with 3-methylglutarylcarnitine(2) was due to pleiotropic effects of other metabolites in a multivariable MR framework, but found it was still causally associated with DBP

672 (Supplementary Information and Supplementary Table 16).

673

New BP-associated SNVs are gene eQTLs across tissues. Sentinel variants from 66 new BP loci were 674 associated ($P < 5 \times 10^{-8}$) with gene expression (or had $r^2 > 0.8$ in 1000G EUR with eQTLs) in publicly 675 available databases (Methods and Supplementary Tables 4 and 11). We performed colocalization for 49 of 676 the 66 BP loci (169 genes) with significant eQTLs available in GTEx v7, jointly across all 48 tissues and 677 the BP traits using HyPrColoc³¹ (Methods), to verify that the eQTL and BP-SNV associations were due to 678 the same SNVs and not due to LD or spurious pleiotropy³². The BP associations and eQTL colocalized at 17 679 BP loci with a single variant (posterior probability, PPa > 0.6), i.e. the expression and BP associations were 680 due to the same underlying causal SNV (Fig. 3 and Supplementary Table 17). A further 10 loci had PPa > 681 0.6 for colocalization of BP associations and eQTL for multiple nearby genes (Fig. 3). Colocalization 682 analyses were also performed for the 35 eQTLs in whole blood from the Framingham Heart Study, and five 683 additional loci were consistent with a shared SNV between BP and gene expression (Supplementary Table 684 17). 685

Given the central role of the kidney in BP regulation, we investigated if BP-associated SNVs from the EAWAS were kidney eQTLs using TRANScriptome of renaL humAn TissuE study and The Cancer Genome Atlas study (n = 285; Methods^{33,34}). We observed significant eQTL associations ($P < 5 \ge 10^{-8}$) at three newly identified BP loci (*MFAP2*, *NFU1*, and *AAMDC*, which were also identified in GTEx) and six at previously published loci (*ERAP1*, *ERAP2*, *KIAA0141*, *NUDT13*, *RP11-582E3.6*, and *ZNF100*;

691 Supplementary Table 18).

692

693 New BP-associated SNVs are pQTLs. Eighteen BP loci had sentinel variants (or were in LD with BP 694 SNVs, $r^2 > 0.8$ in 1000G EUR) that were also protein QTL (pQTL) in plasma. Across the 18 loci, BP-SNVs 695 were pQTLs for 318 proteins (Supplementary Table 19). Low-frequency SNVs in *MCL1* and *LAMA5* were 696 cis-pQTL for MCL1 and LAMA5, respectively. The BP-associated SNV, rs4660253, is a cis-pQTL and cis-697 eQTL for *TIE1* across eight tissues in GTEx including heart (Fig. 3 and Supplementary Table 17). The DBP- associated SNV, rs7776054, is in strong LD with rs9373124, which is a trans-pQTL for erythropoietin, a

699 hormone mainly synthesized by the kidneys, which has links to hypertension.

700

Pathway and enrichment analyses. The over-representation of rare and common BP SNVs in DNaseI-701 hypersensitive sites (DHS), which mark open chromatin, was tested using GARFIELD (Methods and 702 703 Supplementary Table 4). The most significant enrichment in DHS hotspots for SBP-associated SNVs was in fetal heart tissues, with an ~3-fold enrichment compared to ~2-fold in adult heart (Fig. 3 and Supplementary 704 Information). This difference in enrichment was also reflected in fetal muscle compared to adult muscle for 705 SBP-associated SNVs. The most significant enrichment for DBP- and PP-associated SNVs (~3-fold) was in 706 blood vessels (Fig. 3 and Supplementary Information). There was also enrichment across SBP, DBP and PP 707 in fetal and adult kidney and fetal adrenal gland. In support, complementary enrichment analyses with 708 FORGE (Methods) showed similar enrichments including in fetal kidney and fetal lung tissues (Z-score = 709 300; Supplementary Table 13 and Supplementary Information). 710

711

Mendelian randomization with CVD. Twenty-six new BP loci were also associated with cardiometabolic 712 diseases and risk factors in PhenoScanner³⁵ (http://www.phenoscanner.medschl.cam.ac.uk) (Methods, Fig. 713 3, Supplementary Information, and Supplementary Tables 4, 20, and 21). Given that BP is a key risk factor 714 for CVD, we performed Mendelian randomization (MR) analyses to assess the causal relationship of BP 715 with any stroke (AS), ischemic stroke (IS), large artery stroke (LAS), cardio-embolic stroke (CE), small 716 vessel stroke (SVS), and coronary artery disease (CAD) using all the distinct BP-associated SNVs from our 717 study (both known and new; Supplementary Table 4 and Methods). BP was a predictor of all stroke types 718 analyzed and CAD (Fig. 4 and Supplementary Fig. 4). Notably, SBP had the strongest effect on all CVD 719 phenotypes, with the most profound effect on LAS, increasing risk by >2-fold per SD (Supplementary Table 720 22). BP had weakest effect on CE, which may reflect the greater role of atrial fibrillation versus BP in CE 721 risk. Multi-variable MR analyses, including both SBP and DBP, showed that the effect of DBP attenuated to 722 zero once SBP was accounted for (consistent with observational studies³⁷), except for LAS (Fig. 4, 723

Supplementary Table 22, and Methods), where SBP/DBP had a suggestive inverse relationship, perhaps

reflecting arterial stiffening. An inverse relationship between DBP and stroke above age 50 years has also
 been reported³⁷.

727

728 Discussion

Unlike most previous BP studies that focused primarily on common variant associations, the novelty of this 729 investigation is the extensive analysis of rare variants, both individually and in aggregate within a gene. 730 Many of the new rare variants are located in genes that potentially have a role in BP regulation, as evidenced 731 by support from existing mouse models (21 genes) and/or have previously been implicated in monogenic 732 disorders (11 genes) whose symptoms include hyper-/hypotension or impaired cardiac function/development 733 (Supplementary Table 12). For example, rs139600783 (p.Pro274Ser) was associated with increased DBP 734 and is located in the ARHGAP31 gene that causes Adams-Oliver syndrome, which can be accompanied by 735 pulmonary hypertension and heart defects. A further three (of the six) genes that cause Adams-Oliver 736 syndrome are located in BP-associated loci (DLL4¹⁶, DOCK6^{13,15}, and NOTCH1, a new BP locus). A 737 missense variant rs200383755 (p.Ser19Trp, predicted deleterious by SIFT), located in the GATA5, encoding 738 a transcription factor, is associated with increased SBP and DBP. GATA5 mutations cause congenital heart 739 defects, including bicuspid aortic valve and atrial fibrillation, while a Gata5-null mouse model had increased 740 SBP and DBP at 90 days³⁸. 741

Within the known loci, we detected new rare variant associations at several candidate genes, e.g. a 742 rare missense SNV rs1805090 (MAF = 0.0023) in the angiotensinogen (AGT) gene was associated with 743 increased BP independently of the known common variant association. AGT is known to have an important 744 role in BP regulation, and the variant is predicted to be among the top 1% of most deleterious substitutions³⁹. 745 The established common variant at FOXS1 was not associated with BP in the conditional analysis, but new 746 rare variants in *FOXS1* (rs45499294, p.Glu74Lys; MAF = 0.0037) and *MYLK2* (rs149972827; MAF = 747 0.0036; Supplementary Information) were associated with BP. Two BP-associated SNVs (rs145502455, 748 p.Ile806Val; rs117874826, p.Glu564Ala) highlight PLCB3 as a candidate gene. Phospholipase C is a key 749 enzyme in phosphoinositide metabolism, with PLCB3 as the major isoform in macrophages⁴⁰, and a 750 negative regulator of VEGF-mediated vascular permeability, a key process in ischemic disease and cancer⁴¹. 751

PLCB3 deficiency is associated with decreased atherogenesis, increased macrophage apoptosis in 752 atherosclerotic lesions, and increased sensitivity to apoptotic induction in vitro⁴⁰. Variants in SOS2 have 753 previously been linked to kidney development/function⁴² and also cause Noonan syndromes 1 and 9, which 754 are rare inherited conditions characterized by craniofacial dysmorphic features and congenital heart defects, 755 including hypertrophic cardiomyopathy⁴³. Here we report the rare variant rs72681869 (p.Arg191Pro) in 756 757 SOS2 as associated with SBP, DBP, PP, and HTN, highlighting SOS2 as a candidate gene. Previously, we identified a rare missense BP-associated variant in RRAS, a gene causing Noonan syndrome¹³. Our 758 discoveries of rare missense variants at known BP loci provide additional support for candidate genes at 759 these loci. 760

We report new low-frequency variant associations, such as the missense variant rs45573936 (T>C, 761 Ile216Thr) in SLC29A1. The minor allele is associated with both decreased SBP and DBP (Table 1), and the 762 SNV has been shown to affect the function of the encoded protein, equilibrative nucleoside transporter 763 (ENT1)⁴⁴. Best et al.⁴⁵ showed that loss of function of ENT1 caused an (~2.75-fold) increase in plasma 764 adenosine and (~15%) lower BP in mice. Drugs, including dipyridamole and S-(4-Nitrobenzyl)-6-765 thioinosine (NBTI, NBMPR), are currently used as ENT1 inhibitors for their anti-cancer, anti-cardio, and 766 neuro-protective properties, and our results provide the genetic evidence to indicate that ENT1 inhibition 767 might lower BP in humans. 768

We found greater enrichment of SBP-associated SNVs in DHS hotspots in fetal vs. adult heart 769 muscle tissue. These results suggest that BP-associated SNVs may influence the expression of genes that are 770 critical for fetal development of the heart. This is consistent with our finding that some BP-associated genes 771 also cause congenial heart defects (see above). Furthermore, de novo mutations in genes with high 772 expression in the developing heart, as well as in genes that encode chromatin marks that regulate key 773 developmental genes, have previously been shown to be enriched in congenital heart disease patients^{46,47}. A 774 recent study of atrial fibrillation genetics, for which BP is a risk factor, described enrichment in DHS in fetal 775 heart⁴⁸. The authors hypothesized that the corresponding genes acting during fetal development increase risk 776 of atrial fibrillation⁴⁸. Together, these data suggest that early development and/or remodeling of cardiac 777 tissues may be an important driver of BP regulation later in life. 778

779	The BP measures we have investigated here are correlated; amongst the 107 new genetic BP loci,
780	only two are genome-wide significant across all four BP traits (RP11-284M14.1 and VTN; Fig. 2). None of
781	the new loci were unique to HTN (Fig. 2), perhaps as HTN is derived from SBP and DBP, or perhaps due to
782	reduced statistical power for a binary trait. The results from our study indicate rare BP-associated variants
783	contribute to BP variability in the general population, and their identification has provided information on
784	new candidate genes and potential causal pathways. We have primarily focused on the exome array, which
785	is limited. Future studies using both exome and whole genome sequencing in population cohorts (e.g. UKBB
786	and TOPMed) will lead to identification of further rare variant associations and may advance the
787	identification of causal BP genes across the ~1,000 reported BP loci.
788	
789	CONSORTIA
790	
791	LifeLines Cohort Study
792	Rudolf A. de Boer ¹⁸² , Pim van der Harst ^{240,241,242} , Peter van der Meer ²⁴² and Niek Verweij ²⁴⁴
793	
794	EPIC-CVD
795	Adam S. Butterworth ^{1,2,3,68,185} and John Danesh ^{1,2,3,68,185,186}
796	
797	EPIC-InterAct
798	Claudia Langenberg ²⁰ , Panos Deloukas ^{9,21,50,184} , Mark I. McCarthy ^{56,57,122} , Paul W. Franks ^{70,190,191,192} , Olov
799	Rolandsson ¹⁹¹ and Nicholas J. Wareham ²⁰
800	
801	Understanding Society Scientific Group
802	Bram P. Prins ¹ and Eleftheria Zeggini ^{245,246}
803	
804	Million Veterans Program

- Jacklyn N. Hellwege¹⁵, Ayush Giri^{15,16}, Digna R. Velez Edwards⁸⁷, Kelly Cho^{106,107,108}, J. Michael
- Gaziano^{106,107,108}, Csaba P. Kovesdy¹²⁵, Yan V. Sun¹⁵⁰, Philip S. Tsao¹⁵⁴, Peter W. F. Wilson¹⁶⁴, Todd L.
- 807 Edwards²⁵⁰, Adriana M. Hung²⁵¹ and Christopher J. O'Donnell²⁵⁷
- 808

809 ACKNOWLEDGEMENTS

- P. Surendran is supported by a Rutherford Fund Fellowship from the Medical Research Council grant
- 811 MR/S003746/1. N. Lahrouchi is supported by the Foundation "De Drie Lichten" in The Netherlands and the
- 812 Netherlands Cardiovascular Research Initiative, an initiative supported by the Dutch Heart Foundation
- 813 (CVON2012-10 PREDICT and CVON2018-30 PREDICT2). J. N. Hellwege was supported by the
- 814 Vanderbilt Molecular and Genetic Epidemiology of Cancer (MAGEC) Training Program (T32CA160056,
- 815 PI X.-O. Shu). N. Franceschini is supported by the National Institute of Health awards HL140385,
- 816 MD012765 and DK117445. F. W. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research
- 817 Centre. P. Deloukas's work was supported by the British Heart Foundation (BHF) grant RG/14/5/30893. R.
- J. F. Loos is funded by R01DK110113, U01HG007417, R01DK101855, R01DK107786. C. Hayward is
- supported by an MRC University Unit Programme Grant MC_UU_00007/10 (QTL in Health and Disease)
- and MRC University Unit Programme Grant MC PC U127592696. M. I. McCarthy* is a Wellcome Senior
- 821 Investigator (098381; 212259) and an NIHR Senior Investigator (NF-SI-0617-10090). The research was
- supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC),
- and by the Wellcome (090532, 106130, 098381, 203141, 212259). T. Ferreira* is supported by the NIHR
- 824 Biomedical Research Centre, Oxford. M. Tomaszewski is supported by British Heart Foundation
- 825 (PG/17/35/33001 and PG/19/16/34270) and Kidney Research UK (RP_017_20180302). J. Danesh* is funded
- by the National Institute for Health Research (Senior Investigator Award). C. M. Lindgren* is supported by
- the Li Ka Shing Foundation, WT-SSI/John Fell funds and by the NIHR Biomedical Research Centre,
- 828 Oxford, by Widenlife and NIH (5P50HD028138-27). J. M. M. Howson* was funded by the National
- 829 Institute for Health Research (Cambridge Biomedical Research Centre at the Cambridge University
- 830 Hospitals NHS Foundation Trust).

- *The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the
 Department of Health and Social Care.
- Full acknowledgements and full lists of consortia members are provided in the Supplementary Note.

835 AUTHOR CONTRIBUTIONS

- 836 These authors contributed to the drafting of the manuscript: P. Surendran, E.V.F., N.L., I.N., A.C.M.,
- 837 B.M.P., E.B., D.I.C., D.L., P.B.M., and J.M.M.H. The following authors were involved in the central
- analyses: P. Surendran, E.V.F., N.L., I.N., S. Karthikeyan, J. Cook, D.J.L., F.D., C.N.-C., P.B.M., and
- 839 J.M.M.H. All authors critically reviewed and approved the final version of the manuscript. The following
- 840 authors performed bioinformatics analyses: S. Karthikeyan, L.C., B.M., C.Y., A.T.K., J.H.C., B.P.P., I.D.S.,
- 841 C.P.C., J.M.E., A.A., E.B.F., C.N.F., L.A.L., D.S.P., J.R.S., S. Burgess, M.K., J.P., E.Y., M.R.B., M.T.,
- P.B.M., and J.M.M.H. Study Analysts: J.N.H., A.G., V.T., G. Thorleifsson, B.P.P., J.M.E., A.A., P.L.A.,
- 843 L.F.B., J.C.B., V.S.B., J.A.B., E.W.D., F.D., S.F.N., J.D.F., C.F., T.F., H.G., O.G., F.G., D.F.G., X.G.,
- 844 S.E.H., A.S.H., A.H., J.E.H., S.H., S. Kanoni, J.K., M.G.L., R.L., J. Lindström, Y.L., J. Luan, A.M., G.M.,
- N.G.M., H.M., C.M., D.M., M. Müller-Nurasyid, G.P., M.P., A.P., R. Rainer, M. Richard, T.G.R., N.
- 846 Sepúlveda, X.S., A.V.S., J.A.S., A.S., P. Sulem, S. Thériault, U.T., S. Trompet, T.V.V., D.R.V.E., G.V.,
- 847 S.W., S.M.W., J.Y., R.Y., B.Y., W. Zhang, J.Z., W. Zhao (UPenn), W. Zhao (UMich), E.E., L.L.B., K.C.,
- 848 T.L., I.L., M.N., N.W.R., M. Reedik, T.S., I.T., H.R.W., H.Z., S.F., B.J.H., M.I.M., T.D.S., A.S.B., H.H., C.
- Liu, A.K.M., A.P.M., A.C.M., D.I.C., and J.M.M.H. Study Principal Investigators (PI) or Co-PIs: N.F.,
- 850 D.O.M., I.B., P.S.B., C.C., J. Connell, A.F.D., J.M.G., N.G., T.H., F. Karpe, H.A.K., K.K., M. Moitry,
- 851 C.NA.P., O. Pedersen, N.P., A.R., F.R., P. J. Sever, E. Tõnu, C.J.W., P. Almgren, P. Amouyel, F.W.A.,
- 852 A.I.B., M.B., M.L.B., E.P.B., J.E.B., J.C.C., Y.I.C., R.C., D.C., A.C., G.D.S., R.A.d.B., I.J.D., G.D., P.D.,
- 853 E.D.A., P.E., S.B.F., J.F., I.F., M.F., P.W.F., P.F., G.G., T.R.G., L.G., V.G., T.B.H., C.H., B.J.H., K.H., E.I.,
- 854 T.J., M.J., J.W.J., S.L.K., F. Kee, J.S.K., C.K., L.J.L., L. Lind, R.J.F.L., A.a.S.M., L.M., M.I.M., O.M.,
- 855 K.L.M., A.D.M., B.G.N., M.O., C.J.P., S.P., W.P., O. Polasek, D.J.P., A.M.P., M.A.P., C.L.R., K.R.,
- 856 P.M.R., O.R., F.R.R., J.I.R., I.R., V.S., N.J.S., N. Sattar, W.H.S., B.H.S., N. Soranzo, T.D.S., J.M.S., S.S.,
- 857 K.D.T., L.A.T., N.J.T., M.D.T., P.v.d.H., P.v.d.M., V.S.R., N.V., J.V., U.V., D.R. Weir, E.Z., F.J.C.,

- 858 N.J.W., C. Langenberg, M.T., A.S.B., M.J.C., J.D., T.L.E., A.M.H., C.M.L., A.P.M., C.O., B.M.P., D.S.,
- K.S., E.B., D.I.C., D.L., P.B.M., and J.M.M.H. Study phenotyping: A.T.K., J.D.F., M.G.L., Y.L., S.A., E.A.,
- 860 S. Blankenberg, R.d.M., M.D., G.E., A.F., M.L.G.-G., G. Hallmans, G. Heiss, P.J., E.K., A.K., K.K., T.L.,
- L. Lannfelt, W.L., L.W.M., M.N., G.J.P., K.L.R., M. Reedik, F.R., R. Rettig, J.R., P.J. Schreiner, E.L.S.,
- J.S., G. Thorgeirsson, E. Trabetti, T.T., S.T.T., I.T., I.V., A.V., P. Amouyel, J.E.B., J.C.C., Y.I.C., R.A.d.B.,
- 863 J.F., G.G., V.G., B.J.H., F. Kee, J.S.K., L. Lind, R.J.F.L., O.M., W.P., O. Polasek, P.M.R., I.R., N. Sattar,
- 864 W.H.S., T.D.S., J.M.S., P.v.d.H., P.v.d.M., N.V., J.V., D.R. Weir, B.M.P., D.I.C., and D.L.
- 865

866 **COMPETING INTERESTS**

The following authors affiliated with deCODE genetics/Amgen Inc. are employed by the company: Vinicius 867 Tragante, Gudmar Thorleifsson, Anna Helgadottir, Patrick Sulem, Gudmundur Thorgeirsson, Hilma Holm, 868 Daniel F. Gudbjartsson, Unnur Thorsteinsdottir, Kari Stefansson, Bruce Psaty serves on the Steering 869 Committee of the Yale Open Data Access Project funded by Johnson & Johnson. John Danesh reports 870 grants, personal fees and non-financial support from Merck Sharp & Dohme (MSD), grants, personal fees 871 and non-financial support from Novartis, grants from Pfizer, and grants from AstraZeneca outside the 872 submitted work. Adam Butterworth reports grants outside of this work from AstraZeneca, Biogen, Merck, 873 Novartis, and Pfizer and personal fees from Novartis. Veikko Salomaa has participated in a conference trip 874 sponsored by Novo Nordisk and received an honorarium for participating in an advisor board meeting, 875 outside the present study. He also has ongoing research collaboration with Bayer Ltd, outside the present 876 study. Dennis Mook-Kanamori is a part-time clinical research consultant for Metabolon, Inc. Mark I. 877 McCarthy has served on advisory panels for Pfizer, Novo Nordisk, Zoe Global, has received honoraria from 878 Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer 879 Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As 880 of June 2019, he is an employee of Genentech, and a holder of Roche stock. Eric B. Fauman is an employee 881 882 of and owns stock in Pfizer, Inc. Mark J. Caulfield is Chief Scientist for Genomics England, a UK Government company. Joanna M. M. Howson became a full-time employee of Novo Nordisk, and I.N. 883 became a full-time employee of Gilead during revision of the manuscript. 884

- 885
- 886

887 **REFERENCES**

- 888
- Forouzanfar, M.H. *et al.* Global burden of hypertension and systolic blood pressure of at least 110 to
 115 mm Hg, 1990-2015. *JAMA* 317, 165-182 (2017).
- 891 2. Newton-Cheh, C. *et al.* Genome-wide association study identifies eight loci associated with blood
 892 pressure. *Nat. Genet.* 41, 666-676 (2009).
- 893 3. Cho, Y.S. *et al.* A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. *Nat. Genet.* 41, 527-534 (2009).
- 4. Levy, D. *et al.* Genome-wide association study of blood pressure and hypertension. *Nat. Genet.* 41, 677-687 (2009).
- 8975.Kato, N. *et al.* Meta-analysis of genome-wide association studies identifies common variants898associated with blood pressure variation in east Asians. *Nat. Genet.* 43, 531-538 (2011).
- 899 6. Wain, L.V. *et al.* Genome-wide association study identifies six new loci influencing pulse pressure
 900 and mean arterial pressure. *Nat. Genet.* 43, 1005-1011 (2011).
- 7. International Consortium for Blood Pressure Genome-Wide Association Studies *et al.* Genetic
 902 variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* 478, 103-109 (2011).
- 8. Johnson, A.D. *et al.* Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. *Hypertension* **57**, 903-910 (2011).
- 9069.Johnson, T. et al. Blood pressure loci identified with a gene-centric array. Am. J. Hum. Genet. 89,907688-700 (2011).
- 90810.Tragante, V. *et al.* Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies909multiple blood-pressure-related loci. Am. J. Hum. Genet. 94, 349-360 (2014).
- Simino, J. *et al.* Gene-age interactions in blood pressure regulation: a large-scale investigation with
 the CHARGE, Global BPgen, and ICBP Consortia. *Am. J. Hum. Genet.* **95**, 24-38 (2014).
- 12. Kato, N. *et al.* Trans-ancestry genome-wide association study identifies 12 genetic loci influencing
 blood pressure and implicates a role for DNA methylation. *Nat. Genet.* 47, 1282-1293 (2015).
- 91413.Surendran, P. *et al.* Trans-ancestry meta-analyses identify rare and common variants associated with915blood pressure and hypertension. *Nat. Genet.* 48, 1151-1161 (2016).
- 91614.Liu, C. *et al.* Meta-analysis identifies common and rare variants influencing blood pressure and
overlapping with metabolic trait loci. *Nat. Genet.* 48, 1162-1170 (2016).
- Ehret, G.B. *et al.* The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. *Nat. Genet.* 48, 1171-1184 (2016).
- Hoffmann, T.J. *et al.* Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. *Nat. Genet.* 49, 54-64 (2017).
- Warren, H.R. *et al.* Genome-wide association analysis identifies novel blood pressure loci and offers
 biological insights into cardiovascular risk. *Nat. Genet.* 49, 403-415 (2017).
- 92418.Kraja, A.T. *et al.* New blood pressure-associated loci identified in meta-analyses of 475 000925individuals. *Circ. Cardiovasc. Genet.* 10, e001778 (2017).
- Wain, L.V. *et al.* Novel blood pressure locus and gene discovery using genome-wide association
 study and expression data sets from blood and the kidney. *Hypertension* (2017).
- 20. Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci associated with
 blood pressure traits. *Nat. Genet.* 50, 1412-1425 (2018).
- Giri, A. *et al.* Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. *Nat. Genet.* 51, 51-62 (2019).
- Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex trait
 analysis. *Am. J. Hum. Genet.* 88, 76-82 (2011).
- Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203-209 (2018).

- 24. Loh, P.R. *et al.* Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat. Genet.* 47, 284-290 (2015).
- Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* 32, 1493-1501 (2016).
- Wu, M.C. *et al.* Rare-variant association testing for sequencing data with the sequence kernel association test. *Am. J. Hum. Genet.* **89**, 82-93 (2011).
- 942 27. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
- Marouli, E. *et al.* Rare and low-frequency coding variants alter human adult height. *Nature* 542, 186-190 (2017).
- 29. Liu, D.J. *et al.* Exome-wide association study of plasma lipids in > 300,000 individuals. *Nat. Genet.* 49, 1758-1766 (2017).
- 947 30. Finan, C. *et al.* The druggable genome and support for target identification and validation in drug development. *Sci. Transl. Med.* 9, eaag1166 (2017).
- Foley, C.N. *et al.* A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. *bioRxiv*, 592238 (2019).
- 32. Solovieff, N., Cotsapas, C., Lee, P.H., Purcell, S.M. & Smoller, J.W. Pleiotropy in complex traits:
 challenges and strategies. *Nat. Rev. Genet.* 14, 483-495 (2013).
- 33. Xu, X. *et al.* Molecular insights into genome-wide association studies of chronic kidney diseasedefining traits. *Nat. Commun.* 9, 4800 (2018).
- 95534.Rowland, J. *et al.* Uncovering genetic mechanisms of kidney aging through transcriptomics,
genomics, and epigenomics. *Kidney Int.* 95, 624-635 (2019).
- Staley, J.R. *et al.* PhenoScanner: a database of human genotype-phenotype associations. *Bioinformatics* 32, 3207-3209 (2016).
- 95936.Turcot, V. *et al.* Protein-altering variants associated with body mass index implicate pathways that
control energy intake and expenditure in obesity. *Nat. Genet.* **50**, 26-41 (2018).
- 37. Vishram, J.K. *et al.* Impact of age on the importance of systolic and diastolic blood pressures for
 stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project. *Hypertension* 60, 1117-1123 (2012).
- 38. Messaoudi, S. *et al.* Endothelial Gata5 transcription factor regulates blood pressure. *Nat. Commun.* 6, 8835 (2015).
- 39. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* 46, 310-315 (2014).
- 96840.Wang, Z. et al. Phospholipase C beta3 deficiency leads to macrophage hypersensitivity to apoptotic969induction and reduction of atherosclerosis in mice. J. Clin. Invest. 118, 195-204 (2008).
- 41. Hoeppner, L.H. *et al.* Revealing the role of phospholipase Cbeta3 in the regulation of VEGF-induced
 vascular permeability. *Blood* 120, 2167-2173 (2012).
- 42. Li, M. *et al.* SOS2 and ACP1 loci identified through large-scale exome chip analysis regulate kidney development and function. *J. Am. Soc. Nephrol.* 28, 981-994 (2017).
- 43. Tidyman, W.E. & Rauen, K.A. Pathogenetics of the RASopathies. *Hum. Mol. Genet.* 25, R123-R132 (2016).
- 97644.Kim, J.H. *et al.* Functional role of the polymorphic 647 T/C variant of ENT1 (SLC29A1) and its977association with alcohol withdrawal seizures. *PLoS One* 6, e16331 (2011).
- Best, K.A., Bone, D.B., Vilas, G., Gros, R. & Hammond, J.R. Changes in aortic reactivity associated with the loss of equilibrative nucleoside transporter 1 (ENT1) in mice. *PLoS One* 13, e0207198 (2018).
- 46. Zaidi, S. *et al.* De novo mutations in histone-modifying genes in congenital heart disease. *Nature*498, 220-223 (2013).
- 47. Jin, S.C. *et al.* Contribution of rare inherited and de novo variants in 2,871 congenital heart disease
 probands. *Nat. Genet.* 49, 1593-1601 (2017).
- 48. Nielsen, J.B. *et al.* Genome-wide study of atrial fibrillation identifies seven risk loci and highlights
 biological pathways and regulatory elements involved in cardiac development. *Am. J. Hum. Genet.*102, 103-115 (2018).
- 988 989

991 FIGURE LEGENDS

992 Figure 1 | Study design for single variant discovery. a, Exome array-wide association study 993 (EAWAS) of SBP, DBP, PP and HTN. In Stage 1, we performed two fixed effect meta-analyses for 994 each of the blood pressure (BP) phenotypes SBP, DBP, PP and HTN: one meta-analysis including 995 810,865 individuals of European (EUR) ancestry and a second pan-ancestry (PA) meta-analysis 996 including 870,217 individuals of EUR, South Asians (SAS), East Asians (EAS), African Ancestry 997 (AA), Hispanics (HIS) and Native Americans (NAm) (Supplementary Tables 23 and 24; Methods). Summary association statistics for SNVs with $P < 5 \times 10^{-8}$ in Stage 1 that were outside of previously 998 999 reported BP loci (Methods, Supplementary Tables 1 and 25) were requested in independent studies 1000 (up to 448,667 participants; Supplementary Table 24). In Stage 2, we performed both a EUR and a 1001 PA meta-analyses for each trait of Stage 1 results and summary statistics from the additional studies. Only SNVs that were associated with a BP trait at $P < 5 \times 10^{-8}$ in the combined Stage 2 EUR or PA 1002 meta-analyses and had concordant directions of effect across studies ($P_{\text{heterogeneity}} > 1 \times 10^{-4}$; Methods) 1003 1004 were considered significant. Further details are provided in the Methods and Supplementary 1005 Information. b, Rare variant GWAS (RV-GWAS) of SBP, DBP and PP. For SNVs outside of the previously reported BP loci (Methods, Supplementary Tables 1 and 6) with $P < 1 \times 10^{-7}$ in Stage 1, 1006 1007 summary association statistics were requested from MVP (up to 225,112 participants; Supplementary 1008 Table 24). In Stage 2, we performed meta-analyses of Stage 1 and MVP for SBP, DBP and PP in EUR. SNVs that were associated with a BP trait at $P < 5 \times 10^{-8}$ in the combined Stage 2 EUR with 1009 concordant directions of effect across UKBB and MVP ($P_{\text{heterogeneity}} > 1 \times 10^{-4}$; Methods) were 1010 1011 considered significant. Justification of the significance thresholds used and further information on 1012 the statistical methods are detailed in the Methods and Supplementary Information. *Total number of 1013 participants analyzed within each study that provided single variant association summaries following 1014 the data request—EAWAS EUR: Million Veterans Program (MVP: 225,113), deCODE (127,478) 1015 and GENOA (1,505); EAWAS PA: Million Veterans Program (MVP: 225,113 EUR; 63,490 AA; 1016 22,802 HIS; 2,695 Nam; 4,792 EAS), deCODE (127,478 participants from Iceland) and GENOA 1017 (1,505 EUR; 792 AA); RV-GWAS EUR: Million Veterans Program (MVP: 225,112 EUR). 1018 1019 Figure 2 | New BP associations. a, Fuji plot of the genome-wide significant BP-associated SNVs

from the Stage 2 EAWAS and Stage 2 rare variant GWAS. The first four circles (from inside-out) and the last circle (locus annotation) summarize pleiotropic effects, while circles 5 to 8 summarize the genome-wide significant associations. Every dot or square represents a BP-associated locus, and large dots represent novel BP-associated loci, while small dots represent loci containing novel 1024 variants identified in this study, which are in linkage disequilibrium with a variant reported by Evangelou et al.²⁰ and/or Giri et al.²¹. All loci are independent of each other, but due to the scale of 1025 1026 the plot, dots for loci in close proximity overlap. *Loci with rare variant associations. **b**, Venn 1027 diagram showing the overlap of the 107 new BP loci across the analyzed BP traits. c, Functional 1028 annotation from VEP of all the identified rare variants in known and novel regions. d, Plots of minor 1029 allele frequency against effect estimate on the transformed scale for the BP-associated SNVs. Blue 1030 squares are new BP-associated SNVs, black dots represent SNVs at known loci, and red dots are 1031 newly identified distinct BP-associated SNVs at known loci. Effect estimates and SEs for the novel 1032 loci are taken from the Stage 2 EUR analyses (up to 1,164,961 participants), while for the known are 1033 from the Stage 1 analyses (up to 810,865 participants). Results are from the EAWAS where available 1034 and the GWAS (up to 670,472 participants) if the known variants were not on the exome array (data 1035 from Supplementary Tables 1, 3, 7, 8, and 25 were used).

1036

1037 Figure 3 | Annotation of BP loci. a, BP associations shared with eQTL from GTEx through multi-1038 trait colocalization analyses. Expressed gene and the colocalized SNV are provided on the y-axis. BP 1039 trait and eQTL tissues are provided on the x-axis. The color indicates whether the candidate SNV increases BP and gene expression (brown), decreases BP and gene expression (orange), or has the 1040 1041 inverse effects on BP and gene expression (blue). b, Enrichment of BP-associated SNVs in DNase I 1042 hypersensitivity hot spots (active chromatin). The top plot is for SBP, middle is for DBP, and bottom 1043 represents PP. Height of the bar indicates the fold enrichment in the listed tissues, with error bars representing the 95% confidence intervals. The colors represent the enrichment P-value. 1044

1045

1046 Figure 4 | Phenome-wide associations of the new BP loci. a, Modified Fuji plot of the genome-1047 wide significant associated SNVs from the Stage 2 EAWAS and Stage 2 rare variant GWAS (novel 1048 loci only). Each dot resents a novel locus where a conditionally independent variant or a variant in 1049 LD with the conditionally independent variant has been previously associated with one or more traits 1050 unrelated to blood pressure, and each circle represents different trait category (Supplementary Table 1051 20). Locus annotation is plotted in the outer circle, and * sign denotes loci where the conditionally 1052 independent signal maps to a gene which is different to the one closest to the sentinel variant. b, Bar 1053 chart showing the distribution of traits (x-axis) and number of distinct BP-associated variants per trait 1054 (y-axis) that the SNVs in \mathbf{a} are associated with. \mathbf{c} , Bar chart of the number of traits included in \mathbf{b} (y-1055 axis) by trait category (x-axis). The color coding for **a** and **b** is relative to **c**.

1057 Figure 5 | Causal association of BP with stroke and coronary artery disease. Mendelian

1058 randomization analyses of the effect of blood pressure on stroke and coronary artery disease. **a**,

- 1059 Univariable analyses. b, Multivariable analyses (Methods). Analyses were performed using summary
- 1060 association statistics (Methods). The causal estimates are on the odds ratio (OR) scale (the square in
- 1061 the plot). The whiskers on the plots are the 95% confidence intervals for these ORs. Results on the
- 1062 standard deviation scale are provided in Supplementary Table 22. The genetic variants for the
- 1063 estimation of the causal effects in this plot are sets of SNVs after removing the confounding SNVs
- and invalid instrumental variant. OR, odds ratio (*P*-value from the inverse variance weighted two
- 1065 sample Mendelian randomization method). *n*, number of disease cases.
- 1066
- 1067
- 1068
- 1069
- 1070

Locus	rsID	Chr:Pos	Gene	EA/OA	Amino acids	Consequence	Trait	EAF	β	Ρ	Het P	n
Exome a	rray-wide associ	ation study (EAWA	NS)									
10	rs11580946	1:150,551,327	MCL1	A/G	p.Val227Ala	missense	PP	0.016	-0.37	2.74x10 ⁻⁹	0.24	1,159,900
11	rs61747728†	1:179,526,214	NPHS2	T/C	p.Gln229Arg	missense	DBP	0.040	0.26	8.74x10 ⁻¹³	0.22	1,160,530
16	rs4149909	1:242,023,898	EXO1	G/A	p.Ser279Asn	missense	SBP	0.033	0.36	2.46x10 ⁻⁸	0.09	1,158,190
32	rs3821033†	2:219,507,302	ZNF142	T/C	p.Thr1313Ala	missense	DBP	0.033	-0.29	1.42x10 ⁻¹³	0.75	1,160,530
	rs16859180†	2:219,553,468	STK36	T/C	p.Trp477Arg	missense	DBP	0.049	-0.26	1.11x10 ⁻¹⁶	0.34	1,160,530
44	rs145072852	3:101,476,645	CEP97	T/C	p.Phe399Leu	missense	PP	0.004	1.05	1.42x10 ⁻¹³	0.01	1,158,820
46	rs139600783	3:119,109,769	ARHGAP31	T/C	p.Ser274Pro	missense	HTN	0.008	5.85	5.05x10 ⁻⁹	0.19	975,381
50	rs73181210	3:169,831,268	PHC3	C/T	p.Glu692Lys	missense	DBP	0.009	-0.66	9.14x10 ⁻¹⁵	0.04	1,159,580
52	rs11937432†	4: 2,233,709	HAUS3	G/A	p.Thr586lle	missense	DBP	0.046	0.21	9.56x10 ⁻¹⁰	0.26	1,160,520
58	rs1229984	4:100,239,319	ADH1B	T/C	p.His48Arg	missense	PP	0.026	-0.75	2.97x10 ⁻²⁵	0.54	686,104
63	rs143057152	4:149,075,755	NR3C2	T/C	p.His771Arg	missense	SBP	0.003	1.75	4.14x10 ⁻¹⁴	0.22	1,128,880
71	rs61755724	5:132,408,967	HSPA4	A/G	p.Thr159Ala	missense	DBP	0.024	0.26	9.75x10 ⁻⁹	0.36	1,160,530
72	rs33956817	5:137,278,682	FAM13B	C/T	p.Met802Val	missense	SBP	0.044	0.31	1.76x10⁻ ⁸	0.27	1,158,190
77	rs34471628†	5:172,196,752	DUSP1	G/A	p.His187Tyr	missense	DBP	0.039	-0.23	3.00x10 ⁻¹⁰	0.42	1,153,300
85	rs45573936	6: 44,198,362	SLC29A1	C/T	p.lle295Thr	missense missense/splice	DBP	0.027	-0.38	3.70x10 ⁻¹⁹	0.59	1,160,530
100	rs144867634	7:111,580,166	DOCK4	C/T	p.Val326Met	region	DBP	0.025	-0.26	2.62x10 ⁻⁸	0.04	1,160,530
109	rs56335308†	8: 17,419,461	SLC7A2	A/G	p.Met545Val	missense	DBP	0.025	0.31	1.40x10 ⁻¹⁰	0.26	1,160,530
114	rs76767219	8: 81,426,196	ZBTB10	A/C	p.Glu346Ala	missense	SBP	0.034	-0.44	4.41x10 ⁻¹³	0.18	1,160,830
119	rs61732533†	8:145,108,151	OPLAH	A/G	-	synonymous	DBP	0.049	-0.21	2.05x10 ⁻¹⁰	0.86	1,085,170
	rs34674752†	8:145,154,222	SHARPIN	A/G	p.Ser294Pro	missense	DBP	0.049	-0.19	5.89x10 ⁻¹⁰	0.91	1,132,350
146	rs117874826	11: 64,027,666	PLCB3	C/A	p.Ala564Glu	missense	SBP	0.014	0.71	4.67x10 ⁻¹²	0.42	1,153,360
	rs145502455	11: 64,031,030	PLCB3	A/G	p.lle806Val	missense	SBP	0.005	0.90	5.01x10 ⁻⁹	0.04	1,156,310
154	rs141325069	12: 20,769,270	PDE3A	A/G	p.Gln459Arg	missense	SBP	0.003	1.45	6.25x10 ⁻¹¹	0.82	1,134,260
158	rs77357563	12:114,837,349	TBX5	A/C	p.Tyr111Asp	missense	PP	0.005	-1.01	7.72x10 ⁻²²	0.22	1,152,080
159	rs13141	12:121,756,084	ANAPC5	A/G	p.Val630Ala	missense	DBP	0.011	0.52	1.98x10 ⁻¹²	0.63	1,156,950

Table 1 | Rare and low-frequency SNV-blood pressure associations in participants of European ancestry from the (Stage 2) EAWAS and (Stage 2) RV-GWAS that map to new BP loci

168	rs17880989†	14: 23,313,633	MMP14	A/G	p.Ile355Met	missense	DBP	0.027	0.32	2.02x10 ⁻¹⁴	0.95	1,160,530	
169	rs61754158	14: 23,313,033 14: 31,774,324	HEATR5A	T/C	p.ne353ivet p.Arg1670Gly	missense	SBP	0.027	-0.32	6.28x10 ⁻⁹	0.95 0.04	1,119,230	
103	rs72681869	14: 50,655,357	SOS2	C/G	p.Arg191Pro	missense	SBP	0.003	-1.22	2.25x10 ⁻²²	0.04	1,144,040	
170	rs150843673	15: 81,624,929	TMC3	T/G	p.Ser1045Ter	stop/lost	DBP	0.021	0.36	1.43x10 ⁻¹²	0.14	1,154,000	
181	rs61739285	16: 27,480,797	GTF3C1	T/C	p.Ser10451er p.His1630Arg	missense	DBP	0.021	0.30	4.71x10 ⁻¹⁰	0.14	1,155,020	
186	rs62051555	16: 72,830,539	ZFHX3	G/C	p.His1030Alg p.His2014Gln	missense	PP	0.033	0.24	4.71×10 ⁻²⁵	0.04	797,332	
206	rs11699758	20: 60,901,762	LAMA5	G/C T/C	p.lle1757Val	missense	PP	0.048	-0.26	6.68x10 ⁻¹¹	0.43 0.54	1,154,410	
200	rs13039398	20: 60,901,762	LAMA5 LAMA5	A/G	•	missense	PP	0.034	-0.20 -0.26	1.89x10 ⁻¹⁰		1,133,830	
	1813039390	20. 00,902,402	LAMAJ	AG	p.Trp1667Arg	1115561156	ГГ	0.033	-0.20	1.09X10	0.44	1,155,050	
Rare variant – genome-wide association study (RV-GWAS)													
215	rs55833332	1:198,222,215	NEK7	G/C	p.Gly35Arg	missense	PP	0.008	0.62	4.58x10 ⁻⁸	0.08	670,129	
	rs143554274	1:198,455,391	ATP6V1G3	T/C	-	intergenic	PP	0.008	0.71	1.26x10 ⁻⁹	0.14	670,128	
216	rs12135454	1:219,310,461	LYPLAL1-AS1	T/C	-	intron	PP	0.010	-0.62	1.61x10-8	0.22	665,523	
	rs12128471	1:219,534,485	RP11-392017.1	A/G	-	intergenic	PP	0.010	-0.68	2.99x10 ⁻⁹	0.19	670,130	
217	rs114026228	4: 99,567,918	TSPAN5	C/T	-	intron	PP	0.008	-0.65	5.20x10 ⁻⁹	0.03	670,128	
	rs145441283	4: 99,751,794	EIF4E	G/A	-	intergenic	PP	0.010	-0.71	2.01x10 ⁻¹¹	0.08	670,128	
219	rs187207161	6:122,339,304	HMGB3P18	C/T	-	intergenic	PP	0.009	-0.63	2.16x10 ⁻¹⁰	0.02	670,130	
221	rs149165710	8:121,002,676	DEPTOR	A/G	-	intron	PP	0.003	1.32	2.78x10 ⁻¹²	0.03	665,523	
222	rs184289122	10:106,191,229	CFAP58	G/A	-	intron	SBP	0.008	1.31	1.66x10 ⁻¹³	0.53	670,472	
	rs7076147	10:106,250,394	RP11-12704.3	G/A	-	intergenic	SBP	0.010	1.11	1.71x10 ⁻¹⁴	0.75	670,472	
	rs75337836	10:106,272,188	RP11-12704.3	T/G	-	intergenic	SBP	0.010	1.12	2.67x10 ⁻¹⁵	0.54	670,472	
	rs142760284	10:106,272,601	RP11-12704.3	A/C	-	intergenic	SBP	0.009	1.22	2.19x10 ⁻¹⁵	0.92	670,472	
	rs576629818	10:106,291,923	RP11-12704.3	T/C	-	intergenic	SBP	0.009	1.24	1.02x10 ⁻¹⁵	0.71	670,472	
	rs556058784	10:106,322,283	RP11-12704.2	G/A	-	intergenic	SBP	0.009	1.26	4.54x10 ⁻¹⁶	0.57	665,861	
	rs535313355†	10:106,399,140	SORCS3	C/T	-	upstream gene	SBP	0.009	1.36	1.04x10 ⁻¹⁷	0.22	670,472	
	rs181200083†	10:106,520,975	SORCS3	C/A	-	intron	SBP	0.009	1.60	1.08x10 ⁻²¹	0.58	665,861	
	rs540369678†	10:106,805,351	SORCS3	T/A	-	intron	SBP	0.010	1.18	2.29x10 ⁻¹⁴	0.16	670,472	
	rs117627418	10:107,370,555	RP11-45P22.2	T/C	-	intergenic	SBP	0.009	1.11	1.98x10 ⁻¹¹	0.1	665,861	
224	rs138656258	14: 31,541,910	AP4S1	G/T	-	intron	SBP	0.007	-0.93	1.15x10⁻ ⁸	0.13	665,861	
228	rs6061911	20: 60,508,289	CDH4	C/T	-	intron	SBP	0.010	-0.85	4.67x10 ⁻⁸	0.09	665,861	
	rs114580352	20: 60,529,963	TAF4	A/G	-	intron	SBP	0.009	-0.84	1.99x10 ⁻⁸	0.04	665,860	

rs11907239	20: 60,531,853	TAF4	A/G	-	intron	SBP	0.009	-0.82	4.99x10 ⁻⁸	0.05	670,472
rs200383755	20: 61,050,522	GATA5	C/G	p.Trp19Ser	missense	DBP	0.006	1.00	1.01x10 ⁻¹³	0.49	670,172

Newly identified rare and low-frequency SNV-inverse normal transformed blood pressure associations are reported from Stage 2 of the exome array study and genome-wide association study. The reported associations are for the trait with the smallest *P*-value in the Stage 1 meta-analysis; the full results are provided in Supplementary Tables 2 and 7. SNVs are ordered by trait, chromosome, and position. Gene, gene containing the SNV or the nearest gene; rsID, dbSNP rsID; Chr:Pos, Chromosome:NCBI Build 37 position; EA/OA, effect allele (also the minor allele) and other allele; EAF, effect allele frequency based on Stage 1; Consequence, consequence of the SNV to the transcript as annotated by VEP; Amino acids, reference and variant amino acids from VEP; Trait, blood pressure trait for which association is reported; β, effect estimate, in mmHg, from the Stage 2 meta-analysis of the *untransformed* BP trait or the Z-score from the HTN analyses in Stage 2; *P*, *P*-value for association with the listed inverse normal transformed blood pressure trait from the Stage 2 meta-analyses; Het_P, *P*-value for heterogeneity; *n*, sample size. Bold type indicates rare missense variants.

†Novel variants identified in this study that are in linkage disequilibrium (LD: $r^2 > 0.6$ rare SNVs and $r^2 > 0.1$ common SNVs) with a variant that has been reported by Evangelou et al.²⁰ and/or Giri et al.²¹ within +/- 500 kb of the novel variant.

Table 2 | Conditionally independent rare and very low-frequency SNV (MAF < 0.02) associations from exome array at known loci in Stage 1 EUR studies

Locus ID	rsID	Chr:bp	Gene	EA/OA	AA	Consequence	Trait	EAF	β_joint	P_joint	n	Ref
18	rs116245325 rs61757359 rs35479618 **	1: 153665650 1: 153658297 1: 153662423	NPR1 +	T/C A/G A/G	p.Phe1034Leu p.Ser541Gly p.Lys967Glu	Missense Missense Missense	SBP	0.001 0.003 0.017	0.1660 -0.0812 0.0694	7.49x10 -9 6.10x10 -9 1.19x10-28	758,252 794,698 774,862	14 8
28	rs1805090 rs699	1: 230840034 1: 230845794	AGT +	T/G G/A	p.Met392Leu p.Thr268Met	Missense Missense	dbp Dbp	0.002 0.408	0.1070 0.0225	6.00x10 ⁻¹⁰ 2.12x10 ⁻⁴⁵	759,349 806,731	0
94	rs111620813 rs7437940 **	4: 8293193 4: 7887500	HTRA3 + AFAP1	A/G T/C	p.Met269Val	Missense Intron	PP PP	0.011 0.406	-0.0432 -0.0131	1.38x10⁻⁸ 1.62x10 ⁻¹⁶	798,063 806,708	18
102	rs13107325 ** rs4699052	4: 103184239 4: 103188709 4: 104137790	SLC39A8 + CENPE	A/G T/C T/C	p.Phe449Leu p.Thr391Ala -	Missense Missense Intergenic	DBP DBP DBP	0.016 0.072 0.388	-0.0391 -0.0615 -0.0121	3.02x10 ⁻¹⁰ 9.69x10 ⁻⁸⁸ 7.31x10 ⁻¹⁴	803,151 806,731 806,731	6
105	rs6825911 rs33966350	4: 111381638 4: 111431444	ENPEP	T/C A/G	p.Ter413Trp	Intron Stop/lost	DBP DBP	0.205 0.013	-0.0215 0.0735	1.47x10 ⁻²⁸ 2.40x10⁻²⁵	801,965 798,385	
144	rs4712056 ** rs115079907 rs12209452 rs200999181 **	6: 53989526 6: 55924005 6: 55924962 6: 55935568	MLIP COL21A1 ⁺	G/A T/C G/A A/C	p.Val159ll p.Arg882Gly p.Pro821Leu p.Val665Gly	Missense Missense Missense Missense	PP PP PP PP	0.360 0.003 0.049 0.001	0.0091 0.2060 0.0411 0.3350	1.86x10 ⁻⁸ 8.33x10 ⁻¹⁷ 5.49x10 ⁻²⁶ 4.74x10 ⁻⁴³	806,708 783,546 743,036 764,864	14,16,13
	rs35471617 rs2764043 rs1925153 ** rs4294007	6: 56033094 6: 56035643 6: 56102780 6: 57512510	PRIM2	A/G G/A T/C T/G	p.Met343Thr p.Pro277Leu - -	Missense/splice region Missense Intron Splice acceptor	PP PP PP PP	0.073 0.002 0.448 0.379	0.0249 0.1530 -0.0096 0.0096	1.03x10 ⁻¹⁵ 5.11x10⁻¹⁴ 1.03x10 ⁻⁸ 1.13x10 ⁻⁷	806,708 785,643 786,734 632,625	
208	rs507666 rs3025343	9:136149399 9:136478355	ABO LL09NC01- 254D11.1	A/G A/G	- -	Intron Exon (noncoding transcript)	DBP DBP	0.189	-0.0293 -0.0126	7.53x10 ⁻⁴⁷ 4.91x10 ⁻⁷	796,103 806,731	13,15
	rs77273740 rs3025380 rs74853476	9:136501728 9:136501756 9:136501834	DBH DBH DBH	T/C C/G T/C	p.Trp65Arg p.Ala74Gly -	Missense Missense Splice donor	DBP DBP DBP	0.027 0.005 0.002	-0.0846 -0.1030 0.1000	3.85x10 ⁻¹¹ 5.37x10 ⁻¹⁸ 3.69x10 ⁻⁸	790,500 795,263 775,793	
223	rs201422605 rs11187837 rs17417407 rs9419788	10: 95993887 10: 96035980 10: 95931087 10: 96013705	PLCE1	G/A C/T T/G G/A	p.Val678Met - p.Leu548Arg -	Missense Intron Missense Intron	SBP SBP SBP SBP	0.003 0.110 0.167 0.387	-0.0837 -0.0198 -0.0122 0.0137	1.41x10 -7 4.23x10 ⁻¹⁴ 9.97x10 ⁻⁹ 9.63x10 ⁻¹⁶	795,009 801,969 806,735 806,735	7,14
229	rs60889456 rs7126805 **	11: 723311 11: 828916	EPS8L2 + CRACR2B	T/C G/A	p.Leu471Pro p.Gln77Arg	Missense Missense	PP PP	0.017 0.271	0.0303 -0.0134	6.37x10 ⁻⁷ 1.43x10 ⁻¹³	799,021 752,026	17
246*	rs56061986	11: 89182686	NOX4 +	C/T	p.Gly67Ser	Missense	PP	0.003	-0.1080	2.25x10 ⁻¹¹	798,273	17 16

	rs139341533 rs10765211	11: 89182666 11: 89228425		A/C A/G	p.Phe97Leu -	Missense Intron	PP PP	0.004 0.342	-0.0947 -0.0176	6.82x10⁻¹⁴ 8.77x10 ⁻²⁷	785,947 806,708	
250	rs117249984 rs3758911	11: 107375422 11: 107197640	ALKBH8 CWF19L2	A/C C/T	p.Tyr653Asp p.Cys894Tyr	Missense Missense	SBP SBP	0.019 0.341	-0.0304 0.0113	2.90x10 -7 1.54x10 ⁻¹¹	805,695 806,735	16
304	rs61738491	16: 30958481	FBXL19 +	A/G	p.Gln652Arg	Missense	PP	0.010	-0.0460	1.25x10 ⁻⁸	796,459	17,16
130 *	rs35675346 ** rs114280473	16: 30936081 5: 122714092	CEP120 +	A/G A/G	p.Lys10Glu p.Phe712Leu	Missense Missense	РР РР	0.241 0.006	-0.0125 -0.0584	1.06x10 ⁻¹¹ 9.98x10 -8	802,932 805,632	13, 12, 14, 15
	rs2303720	5: 122682334		T/C	p.His947Arg	Missense	PP	0.029	-0.0419	3.44x10 ⁻¹⁸	806,708	
179 *	rs1644318 rs3735080 rs3807375 rs3918234	5: 122471989 7: 150217309 7: 150667210 7: 150708035	PRDM6 GIMAP7 KCNH2 NOS3 +	C/T T/C T/C T/A	۔ p.Cys83Arg - p .Leu982GIn	Intron Missense Intron Missense	PP DBP DBP DBP	0.387 0.237 0.364 0.004	0.0192 -0.0092 -0.0084 -0.0727	2.43x10 ⁻³² 6.56x10 ⁻⁷ 3.94x10 ⁻⁷ 1.33x10 ⁻⁷	790,025 806,731 806,731 786,541	9, 14, 10
	rs891511 ** rs10224002 **	7: 150704843 7: 151415041	PRKAG2	A/G G/A	р.сец902011 - -	Intron	DBP DBP	0.331 0.286	-0.0231 0.0186	1.56x10 ⁻⁴⁰ 7.41x10 ⁻²⁷	778,271 806,731	
												40 70
190 *	rs138582164	8: 95264265	GEM ⁺	A/G	p.Ter199Arg	Stop lost	PP	0.001	0.2810	1.90x10 ⁻¹⁷	735,507	16, 78
190 * 195 *	rs138582164 rs112892337 rs12680655	8: 95264265 8: 135614553 8: 135637337	GEM + ZFAT +	A/G C/G G/C	p.Ter199Arg p.Cys470Ser -	Stop lost Missense Intron	PP SBP SBP	0.001 0.005 0.398	0.2810 -0.0831 0.0118	1.90x10 ⁻¹⁷ 4.39x10 ⁻¹² 1.81x10 ⁻¹³	735,507 792,203 797,982	16, 78 17
	rs112892337	8: 135614553		C/G	. 0	Missense	SBP	0.005	-0.0831	4.39x10 ⁻¹²	792,203	
195 *	rs112892337 rs12680655 rs145878042 rs148755202 rs1471997 rs1126930 ** rs52824916 **	8: 135614553 8: 135637337 12: 48143315 12: 48191247 12: 48723595 12: 49399132 12: 49993678	ZFAT + RAPGEF3 + HDAC7 H1FNT PRKAG1 FAM186B	C/G G/C G/A T/C A/G C/G T/C	p.Cys470Ser p.Pro258Leu p.His166Arg p.Gin174Arg p.Ser98Thr p.Gin582Arg	Missense Intron Missense Missense Missense Missense Missense	SBP SBP SBP SBP SBP SBP SBP	0.005 0.398 0.012 0.016 0.216 0.035 0.088	-0.0831 0.0118 -0.0453 0.0310 0.0130 0.0408 -0.0155	4.39x10 ⁻¹² 1.81x10 ⁻¹³ 9.28x10 ⁻¹⁰ 9.07x10 ⁻⁷ 1.15x10 ⁻¹¹ 1.45x10 ⁻²¹ 1.70x10 ⁻⁸	792,203 797,982 805,791 806,735 806,735 793,216 806,735	17
195 * 259 *	rs112892337 rs12680655 rs145878042 rs148755202 rs1471997 rs1126930 ** rs52824916 ** rs7302981 ** rs61753655 rs1885987 rs34093919	8: 135614553 8: 135637337 12: 48143315 12: 48191247 12: 48723595 12: 49399132 12: 49993678 12: 50537815 17: 1372839 17: 2203025 19: 41117300	ZFAT + RAPGEF3 + HDAC7 H1FNT PRKAG1 FAM186B CERS5 MYO1C + SMG6 LTBP4 +	C/G G/C G/A T/C A/G T/C A/G T/C G/T A/G	p.Cys470Ser p.Pro258Leu p.His166Arg p.Gin174Arg p.Ser98Thr p.Gin582Arg p.Cys75Arg p.Lys866Glu p.Thr341Asn p.Asn715Asp	Missense Intron Missense Missense Missense Missense Missense Missense Missense Missense Missense	SBP SBP SBP SBP SBP SBP SBP SBP SBP SBP	 0.005 0.398 0.012 0.016 0.216 0.035 0.088 0.375 0.011 0.371 0.014 	-0.0831 0.0118 -0.0453 0.0310 0.0130 0.0408 -0.0155 0.0219 0.0653 -0.0127 -0.0631	4.39x10 ⁻¹² 1.81x10 ⁻¹³ 9.28x10 ⁻¹⁰ 9.07x10 ⁻⁷ 1.15x10 ⁻¹¹ 1.45x10 ⁻²¹ 1.70x10 ⁻⁸ 1.52x10 ⁻⁴¹ 6.48x10 ⁻¹⁸ 3.94x10 ⁻¹⁵ 4.18x10 ⁻²⁰	792,203 797,982 805,791 806,735 806,735 806,735 806,735 806,735 806,735 806,735 806,735 806,735	17 16, 13
195 * 259 * 312 *	rs112892337 rs12680655 rs145878042 rs148755202 rs1471997 rs1126930 ** rs52824916 ** rs7302981 ** rs61753655 rs1885987	8: 135614553 8: 135637337 12: 48143315 12: 48191247 12: 48723595 12: 49399132 12: 49993678 12: 50537815 17: 1372839 17: 2203025	ZFAT + RAPGEF3 + HDAC7 H1FNT PRKAG1 FAM186B CERS5 MYO1C + SMG6	C/G G/C G/A T/C A/G C/G T/C A/G T/C G/T	p.Cys470Ser p.Pro258Leu p.His166Arg p.GIn174Arg p.Ser98Thr p.GIn582Arg p.Cys75Arg p.Lys866Glu p.Thr341Asn	Missense Intron Missense Missense Missense Missense Missense Missense Missense Missense	SBP SBP SBP SBP SBP SBP SBP SBP SBP	0.005 0.398 0.012 0.016 0.216 0.035 0.088 0.375 0.011 0.371	-0.0831 0.0118 -0.0453 0.0310 0.0130 0.0408 -0.0155 0.0219 0.0653 -0.0127	4.39x10 ⁻¹² 1.81x10 ⁻¹³ 9.28x10 ⁻¹⁰ 9.07x10 ⁻⁷ 1.15x10 ⁻¹¹ 1.45x10 ⁻²¹ 1.70x10 ⁻⁸ 1.52x10 ⁻⁴¹ 6.48x10 ⁻¹⁸ 3.94x10 ⁻¹⁵	792,203 797,982 805,791 806,735 806,735 806,735 806,735 806,735 806,735	17 16, 13 17, 16

GCTA was used to perform conditional analyses of the meta-analysis results from the exome array study from the Stage 1 meta-analysis of EUR studies in known blood pressure regions (defined in Supplementary Table 1). All SNVs had P < 0.0001 for heterogeneity. The trait selected in this table is the trait for which the rare variant had the smallest *P*-value. We provide all conditionally independent variants at these loci, i.e. rare, very low frequency (MAF < 0.02), low frequency, and common. The full detailed listing of results is provided in Supplementary Table 8. Bold font highlights variants with MAF < 0.02. Locus ID, the known locus identifier used in Supplementary Table 1; Chr:Position,

chromosome and NCBI Build 37 physical position; EA/OA, Effect allele/other allele; AA, amino acid change; Effect, predicted consequence of the SNV from VEP; EAF, effect allele frequency; β_joint, effect estimate for the SNV in the joint analysis from GCTA; *P_joint*, the *P*-value for association of the rare variant from the joint analysis in GCTA; Gene, nearest gene; Trait, blood pressure trait analyzed; Ref, reference of the first reports of association in the listed region.

*Indicates that one or more of the previously reported variants in the locus were not on exome array.

**Indicates that the listed variant is the known variant or its proxy ($r^2 > 0.8$ in 1000G EUR).

+Indicates that the listed gene had an unconditional SKAT P-value < 2 x 10⁻⁶ (see Supplementary Table 9).

_								Uncondi	tional SN	IV analysis	FINEMAP o	output		Ref
Locus ID	rsID	Chr:Position	Gene	Info	EA/ OA	Consequence	Trait	EAF	β	<i>P</i> -value	Common SNVs in top configuration	PP of n SNVs	log₁₀BF	-
5	rs41300100	1:11908146	NPPA	0.82	G/C	5' UTR	SBP	0.010	-0.10	4.70x10 ⁻²¹	rs2982373, rs5066, rs55892892	0.55	122.50	9,2,79
18	rs756799918	1:153464738	RN7SL44P	0.89	T/C	intergenic	SBP	0.0004	0.26	4.30x10 ⁻⁷	rs12030242	0.36	27.49	14
28	rs1805090	1:230840034	AGT	NA	T/G	missense	SBP	0.0025	0.11	6.80x10 ⁻⁸	rs3889728, rs2493135	0.79	26.23	8
28	rs539645495	1:230860071	RP11- 99J16A.2	0.97	G/A	intron, non- coding transcript	DBP	0.0024	0.13	3.20x10 ⁻⁹	rs2493135, rs3889728	0.83	30.97	8
33	rs56152193	2:20925891	LDAH	0.76	C/G	intron	PP	0.0006	-0.23	8.10x10 ⁻⁷	rs7255	0.36	17.95	17, 16
55	rs759606582	2:178325956	AGPS	0.96	G/A	intron	PP	0.0003	0.29	1.90x10 ⁻⁷	rs56726187	0.57	7.48	16
72	rs555934473	3:48899332	SLC25A20	0.74	T/G	intron	DBP	0.0012	-0.17	2.50x10 ⁻⁶	rs36022378, rs6442105, rs6787229	0.25	35.71	17, 16, 6, 11
73	rs76920163	3:53857055	CHDH	0.96	G/T	intron	SBP	0.0059	0.10	3.80x10 ⁻¹³	rs3821843, rs7340705, rs11707607	0.58	29.45	18, 16
	rs144980716	3:53776904	CACNA1D	0.91	A/G	intron	PP	0.0065	0.07	2.60x10 ⁻⁸	rs36031811, rs77347777	0.57	18.42	
85	rs547947160	3:141607335	ATP1B3	0.75	G/A	intron	PP	0.0008	0.20	6.00x10 ⁻⁶	rs6773662	0.54	7.040	13
86	rs545513277	3:143113550	SLC9A9	0.70	A/G	intron	PP	0.0006	-0.24	6.90x10 ⁻⁶	rs1470121	0.56	11.97	16
92	rs186525102	3:185539249	IGF2BP2	0.85	A/G	intron	SBP	0.0086	-0.06	6.70x10 ⁻⁷	rs4687477	0.56	8.08	17
94	rs111620813	4:8293193	HTRA3	NA	A/G	missense	PP	0.0100	-0.05	2.00x10 ⁻⁶	rs28734123	0.53	12.54	18

Table 3 | Newly identified independent BP-associated rare SNVs (MAF ≤ 0.01) at known loci in UK Biobank only

132	rs181585444	5:129963509	AC005741.2	0.83	C/T	intergenic	DBP	0.0003	-0.30	3.80x10 ⁻⁶	rs274555	0.55	10.70	14, 13
137	rs546907130	6:8156072	EEF1E1	0.90	T/C	intergenic	SBP	0.0017	-0.14	1.90x10 ⁻⁷	rs3812163	0.70	8.57	16
141	rs72854120	6:39248533	KCNK17	0.91	C/T	intergenic	SBP	0.0073	-0.08	3.10x10 ⁻⁹	rs2561396	0.76	10.49	16
141	rs72854118	6:39248092	KCNK17	0.91	G/A	intergenic	DBP	0.0072	-0.07	2.70x10 ⁻⁷	rs1155349	0.85	11.12	16
164	rs138890991	7:40804309	SUGCT	0.94	C/T	intron	PP	0.0100	0.06	1.60x10 ⁻⁷	rs17171703	0.77	19.08	17
179	rs561912039	7:150682950	NOS3	0.74	T/C	intergenic	DBP	0.0017	-0.13	6.40x10 ⁻⁶	rs3793341, rs3918226, rs6464165, rs7788497, rs891511	0.34	81.75	9,14,10
183	rs570342886	8:23380012	SLC25A37	0.85	C/G	intergenic	DBP	0.0001	-0.48	9.80x10 ⁻⁷	rs7842120	0.58	15.74	16
190	rs201196388	8:95265263	GEM	NA	T/C	splice donor	PP	0.0005	0.26	2.40x10 ⁻⁹	rs2170363	0.34	31.80	16, 78
193	rs532252660	8:120587297	ENPP2	0.79	T/C	intron	DBP	0.0025	-0.11	4.10x10 ⁻⁷	rs7017173	0.81	26.53	6
193	rs181416549	8:120678125	ENPP2	0.84	A/G	intron	PP	0.0026	0.20	5.10x10 ⁻²¹	rs35362581, rs80309268	0.95	113.21	6
212	rs138765972	10:20554597	PLXDC2	0.94	C/T	intron	DBP	0.0075	-0.07	4.40x10 ⁻⁸	rs61841505	0.49	9.06	16
219	rs192036851	10:64085523	RP11- 120C12.3	0.92	C/T	intergenic	SBP	0.0062	0.06	6.40x10 ⁻⁶	rs10995311	0.28	19.55	16, 13
234	rs150090666	11:14865399	PDE3B	NA	T/C	stop gained	DBP	0.0010	-0.16	5.20x10 ⁻⁷	rs11023147, rs2597194	0.55	12.93	16
242	rs139620213	11:61444612	DAGLA	0.89	T/C	upstream gene	PP	0.0019	0.11	5.90x10 ⁻⁶	rs2524299	0.48	6.64	15
246	rs540659338	11:89183302	NOX4	0.85	C/T	intron	PP	0.0027	-0.14	2.60x10 ⁻¹⁰	rs2289125, rs494144	0.62	58.09	17, 16
260	rs186600986	12:53769106	SP1	0.91	A/G	upstream gene	PP	0.0030	-0.09	1.10x10 ⁻⁶	rs73099903	0.48	12.91	19
266	rs137937061	12:111001886	PPTC7	0.74	A/G	intron	SBP	0.0048	-0.09	1.30x10 ⁻⁶	rs9739637, rs35160901, rs10849937, rs3184504	0.34	55.74	16, 4, 5
268	rs190870203	12:123997554	RILPL1	0.85	T/G	intron	PP	0.0020	0.12	1.70x10 ⁻⁷	rs4759375	0.72	9.50	13
270	rs541261920	13:30571753	RP11- 629E24.2	0.79	G/C	intergenic	SBP	0.0005	0.24	9.20x10 ⁻⁶	rs7338758	0.54	10.09	16
281	rs149250178	14:100143685	629E24.2 HHIPL1	0.75	A/G	3' UTR	DBP	0.0004	-0.29	2.30x10 ⁻⁶	rs7151887	0.51	7.93	16
201				0.10		0.011	001	5.0001	0.20			0.01	1.00	

299	rs139491786	16:2086421	SLC9A3r2	NA	T/C	missense	DBP	0.0068	-0.12	1.60x10 ⁻²⁰	rs28590346, rs34165865, rs62036942, rs8061324	0.57	50.80	16
304	rs2234710	16:30907835	BCL7C	0.79	T/G	upstream gene	SBP	0.0075	-0.08	2.30x10 ⁻⁹	-	0.52	6.29	17, 16
304*	rs148753960	16:31047822	STX4	0.89	T/C	intron	PP	0.0099	-0.07	1.80x10 ⁻⁹	rs7500719	0.42	12.21	17, 16
317	rs756906294	17:42323081	SLC4A1	0.73	T/C	downstream gene	PP	0.0030	0.01	8.30x10 ⁻⁶	rs66838809	0.27	18.94	17
322	rs16946721	17:61106371	TANC2	0.91	G/A	intron	DBP	0.0100	-0.07	1.40x10 ⁻¹¹	rs1867624, rs4291	0.51	20.91	17, 16
333	rs55670943	19:11441374	RAB3D	0.87	C/T	intron	SBP	0.0085	-0.10	2.10x10 ⁻¹⁷	rs12976810, rs4804157, rs160838, rs167479	0.78	85.45	13-15
346*	rs149972827	20:30413439	MYLK2	0.98	A/G	intron	SBP	0.0036	-0.10	6.20x10 ⁻⁹	-	0.85	9.86	16
362	rs115089782	22:42329632	CENPM	0.93	T/C	intergenic	SBP	0.0001	0.53	4.20x10 ⁻⁶	rs139919	0.44	14.12	17, 13

2 FINEMAP²⁵ was used to identify the most likely causal variants within the known loci (defined in Supplementary Table 1) using the BOLT-LMM results in UKBB,

3 the full detailed listing of results is provided in Supplementary Table 8. Locus ID, the known locus identifier provided in Supplementary Table 1; Chr:Position,

4 chromosome and physical position in Build 37; Info, imputation information score, NA indicates that the SNV was genotyped and not imputed; EA/OA, Effect

5 allele and other allele, respectively; AA, amino acid change; Effect, predicted effect of the listed SNV; EAF, effect allele frequency; β, single variant effect

6 estimate for the rare variant in the BOLT-LMM analysis; *P*-value, the single variant *P*-value from the mixed model in the BOLT-LMM analysis; PP of n SNVs, the

posterior probability of the number of causal variants; Log₁₀BF, log₁₀ Bayes factor for the top configuration; Gene, nearest gene; Trait, blood pressure trait

8 analyzed; Ref, reference of the first reports of association in the listed region.

9 rs540659338 identified in UK Biobank in *NOX4* has $r^2 = 1$ in 1000G EUR with rs56061986 identified in the GCTA analysis in Table 4.

10 *Variants at these loci are in LD with GCTA variants (Table 2): at locus 304, $r^2 = 0.876$ between rs148753960 and rs61738491; at locus 346, $r^2 = 0.952$ between

11 rs149972827 and rs45499294.

Online Methods

14 The statistical methods used and analytical packages used are further detailed in the Life Sciences15 Reporting Summary.

17	Participants. The cohorts contributing to Stage 1 of the EAWAS comprised 92 studies from four
18	consortia (CHARGE, CHD Exome+, GoT2D:T2DGenes, ExomeBP), and UK Biobank (UKBB)
19	totalling 870,217 individuals of European (EUR, $n = 810,865$), African Ancestry (AA, $n = 21,077$),
20	South Asian (SAS, $n = 33,689$), and Hispanic (HIS, $n = 4,586$) ancestries. Study-specific
21	characteristics, sample quality control and descriptive statistics for the new studies are provided in
22	Supplementary Tables 23 and 24 (and in Supplementary Table 1 and 2 of Surendran et al. ¹³
23	(https://media.nature.com/original/nature-assets/ng/journal/v48/n10/extref/ng.3654-S2.xlsx) and
24	Supplementary Table 20 of Liu et al. ¹⁴ (<u>https://media.nature.com/original/nature-</u>
25	assets/ng/journal/v48/n10/extref/ng.3660-S1.pdf) for the previously published studies).
26	For EAWAS, summary association statistics were requested (for the SNVs with $P < 5 \times 10^{-8}$,
27	outside of known BP loci) from the following cohorts: 127,478 Icelanders from deCODE; 225,113
28	EUR, 63,490 AA, 22,802 HIS, 2,695 NAm (Native Americans), and 4,792 EAS (East Asians) from
29	the Million Veterans Program (MVP); and 1,505 EUR and 792 AA individuals from the Genetic
30	Epidemiology Network of Arteriopathy (GENOA). In total, following the data request, 448,667
31	individuals of EUR (<i>n</i> = 354,096), AA (<i>n</i> = 63,282), HIS (<i>n</i> = 22,802), NAm (<i>n</i> = 2,695), and EAS
32	(n = 4,792) ancestries were available for meta-analyses with Stage 1. Study specific characteristics
33	are provided in Supplementary Tables 23 and 24.
34	Stage 1 of the RV-GWAS used data from 445,360 EUR individuals from UKBB
35	(Supplementary Tables 23 and 24, Supplementary Information), and rare variants were followed up

36 in a data request involving 225,112 EUR individuals from MVP.

All participants provided written informed consent, and the studies were approved by their
 local research ethics committees and/or institutional review boards. The BioVU biorepository
 performed DNA extraction on discarded blood collected during routine clinical testing, and linked to
 de-identified medical records.

- 41
- 42 Phenotypes. SBP, DBP, PP and HTN were analyzed. Details of the phenotype measures for the
 43 previously published studies can be found in the Supplementary Information of the Surendran *et al.*44 and Liu *et al.* papers (https://media.nature.com/original/nature-

45 <u>assets/ng/journal/v48/n10/extref/ng.3654-S2.xlsx; https://media.nature.com/original/nature-</u>

46 assets/ng/journal/v48/n10/extref/ng.3660-S1.pdf), and further details of the additional studies are 47 provided in Supplementary Table 24 and Supplementary Information. Typically, the average of two 48 baseline measurements of SBP and DBP were used. For individuals known to be taking BP-lowering 49 medication, 15 and 10 mmHg were added to the raw SBP and DBP values, respectively, to obtain medication-adjusted values⁴⁹. PP was defined as SBP minus DBP after medication adjustment. For 50 51 HTN, individuals were classified as hypertensive cases if they satisfied at least one of the following 52 criteria: (i) SBP \ge 140 mmHg, (ii) DBP \ge 90 mmHg, or (iii) use of antihypertensive or BP-lowering 53 medication. All other individuals were considered controls. Further information on study-specific BP 54 measurements is provided in Supplementary Table 24. Residuals from the null model obtained after regressing the medication-adjusted trait on the covariates (age, age², sex, BMI, principal components 55 56 (PCs) to adjust for population stratification, in addition to any study-specific covariates) within a 57 linear regression model were ranked and inverse normalized (Supplementary Information).

58

Genotyping. The majority of the studies were genotyped using one of the Illumina HumanExome
BeadChip arrays (Supplementary Table 24). An exome chip quality control standard operating
procedure (SOP: https://ruderd02.u.hpc.mssm.edu/Exome-chip-QC.pdf) developed by A. Mahajan,

N.R.R. and N.W.R. at the Wellcome Trust Centre for Human Genetics, University of Oxford was used by some studies for genotype calling and quality control, while the CHARGE implemented an alternative approach⁵⁰ (Supplementary Table 24 and Supplementary Tables 3 and 21, respectively, of Surendran et al.¹³ and Liu et al.¹⁴). All genotypes were aligned to the plus strand of the human genome reference sequence (build 37) before any analyses and any unresolved mappings were removed. UKBB, MVP, and deCODE were genotyped using GWAS arrays (Supplementary Table 24).

69

70 Exome array meta-analyses. Study-specific analyses were performed to test for the association of 71 247,315 SNVs with SBP, DBP, PP and HTN in 810,865 individuals of European ancestry (75 EUR 72 studies) and additionally in 59,352 individuals of non-European ancestry comprising of SAS (5 73 studies), AA (10 studies), and HIS (2 studies) individuals (Supplementary Information). Study-74 specific association summaries were meta-analyzed in Stage 1 using an inverse-variance-weighted fixed-effect meta-analyses implemented in METAL⁵². Fixed effect and random effects meta-analyses 75 76 showed concordant results (Supplementary Table 2). For the binary trait (HTN), we performed 77 sample-size-weighted meta-analysis.

78 Minimal inflation in the association test statistic, λ , was observed ($\lambda = 1.18$ for SBP, 1.20 for 79 DBP, 1.18 for PP, and 1.18 for HTN in the EUR meta-analyses; and $\lambda = 1.19$ for SBP, 1.20 for DBP, 80 1.18 for PP, and 1.16 for HTN in the PA meta-analyses). The meta-analyses were performed 81 independently at three centres, and results were found to be concordant across the centres. Following Stage 1, SNVs outside of known BP-associated regions with $P < 5 \times 10^{-8}$ were looked up 82 83 in individuals from the MVP, deCODE, and GENOA studies (data request). Two meta-analyses of 84 the three additional studies for each trait were performed by two independent analysts, one involving 85 EUR individuals (354,096 participants) only and one PA (448,667 participants). Likewise, two Stage 86 2 meta-analyses for each trait were performed by two independent analysts, one EUR (1,167,961

participants) and one PA (1,318,884 participants). SNVs with (a conservative) $P < 5 \times 10^{-8}$ in the Stage 2 meta-analysis, with consistent directions of effect in Stage 1 and data request studies and no evidence of heterogeneity (P > 0.0001), were considered potentially novel⁵³.

90

91 **RV-GWAS.** Rare SNVs with $P < 5 \times 10^{-8}$ (a widely accepted significance threshold^{54,55}) in the 92 inverse variance-weighted meta-analysis of UKBB and MVP, with consistent directions of effect in 93 Stage 1 and MVP and no evidence of heterogeneity (P > 0.0001), were considered potentially novel. 94

95 Quality control. As part of the sample QC, plots comparing inverse of the standard error as a 96 function of the square root of study sample size for all studies were manually reviewed for each trait, 97 and phenotype-specific study outliers were excluded. In addition, inflation of test static was 98 manually reviewed for each study and for each phenotype and confirmed minimal or no inflation 99 prior to Stage 1 meta-analyses. For EAWAS and RV-GWAS, we performed our own QC for 100 genotyped variants as we were specifically interested in rare variants and knew that these were most 101 vulnerable to clustering errors. Full details of UKBB OC are provided in the Supplementary Note. 102 To ensure that the variants we reported are not influenced by technical artefacts and not specific to a 103 certain ancestry, we ensured that there was no heterogeneity and also that the variants had consistent 104 direction of effects between Stage 1 and the data request studies (MVP+deCODE+GENOA). In 105 addition, we ensured that the association was not driven by a single study. For variants reported in 106 RV-GWAS and EAWAS, we reviewed the cluster plots for clustering artefacts and removed poorly 107 clustered variants. Lastly, for RV-GWAS, if the variant was available in UKBB whole exome data 108 (~50K individuals), we ensured that the minor allele frequencies were consistent with the imputed 109 MAF despite restricting the reporting of only variant with a good imputation quality (INFO > 0.8). 110

111 Definition of known loci. For each known variant, pairwise LD was calculated between the known 112 variant and all variants within the 4-Mb region in the 1000 Genomes phase 3 data restricted to samples of European (EUR) ancestry. Variants with $r^2 > 0.1$ were used to define a window around 113 114 the known variant. The region start and end were defined as the minimum position and maximum position of variants in LD within the window ($r^2 > 0.1$), respectively. Twelve variants were not in 115 116 1000 Genomes, and for these variants, a ±500-kb window around the known variant was used. The 117 window was extended by a further 50 kb and overlapping regions were merged (Supplementary 118 Table 1).

119

120 **Conditional analyses.** Within the new BP loci, we defined a region based on LD (Supplementary 121 Table 1) within which conditional analysis was performed (five variants were not in the 1000G 122 panel, and for these we established a ±500-kb window definition). Conditional and joint association analysis as implemented in Genome-wide Complex Trait Analysis (GCTA v1.91.4)²² was performed 123 124 using the EAWAS results to identify independent genetic variants associated with BP traits within 125 newly identified and known regions available in the exome array. We restricted this analysis to the 126 summary data from Stage 1 EUR EAWAS meta-analyses (n = 810,865) as LD patterns were 127 modelled using individual level genotype data from 57,718 EUR individuals from the CHD Exome+ consortium. Variants with $P_{\text{joint}} < 1 \times 10^{-6}$ were considered conditionally independent. 128 We used the UKBB GWAS results and FINEMAP²⁵ v1.1 to fine-map the known BP-129 130 associated regions in order to identify rare variants that are associated with BP independently of the 131 known common variants (Supplementary Note; due to lack of statistical power, we did not use 132 UKBB GWAS data alone to perform conditional analyses within the new EAWAS loci). For each 133 known region, we calculated pairwise Pearson correlation for all SNVs within a 5-Mb window of the 134 known SNVs using LDstore v1.1. Z-scores calculated in the UKBB single-variant association

analyses were provided as input to FINEMAP along with the correlation matrix for the region. We

136 selected the configuration with the largest Bayes Factor (BF) and largest posterior probability as the 137 most likely causal SNVs. We considered causal SNVs to be significant if the configuration cleared a 138 threshold of $log_{10}BF > 5$ and if the variants in the configuration had an unconditional association of $P \le 1 \times 10^{-6}$. We examined the validity of the SNVs identified for the most likely configuration by 139 checking marginal association P-values and LD (r^2) within UKBB between the selected variants. For 140 141 loci that included rare variants identified by FINEMAP, we validated the selected configuration 142 using a linear regression model in R. 143 144 Gene-based tests. Gene-based tests were performed using the sequence kernel association test (SKAT)²⁶ as implemented in the rareMETALS package version 7.1 145 146 (https://genome.sph.umich.edu/wiki/RareMETALS) (which allows for the variants to have different 147 directions and magnitudes of effect) to test whether rare variants in aggregate within a gene are 148 associated with BP traits. For the EAWAS, two gene-based meta-analyses were performed for 149 inverse-normal transformed DBP, SBP, and PP, one of EUR and a second PA including all studies 150 with single-variant association results and genotype covariance matrices (up to 691,476 and 749,563 151 individuals from 71 and 88 studies were included in the EUR and PA gene-based meta-analyses, 152 respectively). 153 In UKBB, we considered summary association results from 364,510 unrelated individuals only. We annotated all SNVs on the exome array using VEP²⁷. A total of 15,884 (EUR) and 15,997 154 155 genes (PA) with two or more variants with MAF ≤ 0.01 annotated with VEP as high or moderate effects were tested. The significance threshold was set at $P < 2.5 \times 10^{-6}$ (Bonferroni adjusted for 156

157 ~20,000 genes).

A series of conditional gene-based tests were performed for each significant gene. To verify the gene association was due to more than one variant (and not due to a single sub-genome-wide significance threshold variant), gene tests were conditioned on the variant with the smallest *P*-value

in the gene (top variant). Genes with $P_{\text{conditional}} < 1 \times 10^{-4}$ were considered significant, which is in line 161 with locus-specific conditional analyses used in other studies⁵⁶. In order to ensure that gene 162 163 associations located in known or newly identified BP regions (Supplementary Note and Supplementary Table 1) were not attributable to common BP-associated variants, analyses were 164 165 conditioned on the conditionally independent known/novel common variants identified using GCTA 166 within the known or novel regions, respectively, for the EAWAS (or identified using FINEMAP for the GWAS). Genes mapping to either known or novel loci with $P_{\text{conditional}} < 1 \times 10^{-5}$, were considered 167 168 significant. The P-value to identify gene-based association not driven by a single variant was set in 169 advance of performing gene-based tests and was based on an estimation of the potential number of 170 genes that could be associated with BP. 171

172 Mendelian randomization with CVDs. We used two-sample MR to test for causal associations 173 between BP traits and any stroke (AS), any ischemic stroke (IS), large artery stroke (LAS), 174 cardioembolic stroke (CE), small vessel stroke (SVS), and coronary artery disease (CAD). All the 175 new and known BP-associated SNVs (including conditionally independent SNVs) listed in 176 Supplementary Tables 2, 3, 5, 7 and 8, were used as instrumental variables (IVs). In addition to trait 177 specific analyses, we performed an analysis of "generic" BP, in which we used the SNVs associated 178 with any of the traits. Where variants were associated with multiple BP traits, we extracted the 179 association statistics for the trait with the smallest P-value (or the largest posterior probability for the 180 known loci). To exclude potentially invalid (pleiotropic) genetic instruments, we used 181 PhenoScanner³⁵ to identify SNVs associated with CVD risk factors, cholesterol 182 (LDL/HDL/triglycerides (TG)), smoking, type 2 diabetes (T2D) and atrial fibrillation (AF) 183 (Supplementary Table 22) and removed these from the list of IVs. We extracted estimates for the 184 associations of the selected instruments with each of the stroke subtypes from the MEGASTROKE

185	PA GWAS results (67,162 cases; 454,450 controls) ⁶³ and from a recent GWAS for CAD ⁶⁴ . We
186	applied a Bonferroni correction ($P < 0.05/6 = 0.0083$) to account for the number of CVD traits.
187	We used the inverse-variance weighting method with a multiplicative random-effects because we
188	had hundreds of IVs for BP65. We performed MR-Egger regression, which generates valid estimates
189	even if not all the genetic instruments are valid, as long as the Instrument Strength Independent of
190	Direct Effect assumption holds ⁶⁶ . We note that MR-Egger has been shown to be conservative ⁶⁶ , but
191	has the useful property that the MR-Egger-intercept can give an indication of (unbalanced)
192	pleiotropy, which allowed us to test for pleiotropy amongst the IVs. We used MR-PRESSO to detect
193	outlier IVs ⁶⁷ . To assess instrument strength, we computed the F-statistic ⁶⁸ for the association of
194	genetic variants with SBP, DBP and PP, respectively (Supplementary Information and
195	Supplementary Table 22). We also assessed heterogeneity using the Q-statistic. Although these
196	methods may have different statistical power, the rationale is that, if these methods give a similar
197	conclusion regarding the association of BP and CVD, then we are more confident in inferring that
198	the positive results are unlikely to be driven by violation of the MR assumptions ⁶⁹ .
199	Moreover, we used multivariable MR (mvMR) to estimate the effect of multiple variables on
200	the outcome ^{65,70} . This is useful when two or more correlated risk factors are of interest, e.g. SBP and
201	DBP, and may help to understand whether both risk factors exert a causal effect on the outcome, or
202	whether one exerts a leading effect on the outcome. Thus, we used multiple genetic variants
203	associated with SBP and DBP to simultaneously estimate the causal effect of SBP and DBP on
204	CVDs.
205	All analyses were performed using R version 3.4.2 with R packages 'TwoSampleMR' and
206	'MendelianRandomization' and "MRPRESSO".
207	
208	Metabolite quantitative trait loci and Mendelian randomization analyses. Plasma metabolites

were measured in up to 8,455 EUR individuals from the INTERVAL study^{71,72} and up to 5,841 EUR

210	individuals from EPIC-Norfolk ⁷³ using the Metabolon HD4 platform. In both studies, 913
211	metabolites passed QC and were analyzed for association with ~17 million rare and common
212	genetic variants. Genetic variants were genotyped using the Affymetrix Axiom UK Biobank array
213	and imputed using the UK10K+1000Genomes or the HRC reference panel. Variants with INFO >
214	0.3 and MAC $>$ 10 were analyzed. Phenotypes were log-transformed within each study, and
215	standardized residuals from a linear model adjusted for study-specific covariates were calculated
216	prior to the genetic analysis. Study-level genetic analysis was performed using linear mixed models
217	implemented in BOLT-LMM to account for relatedness within each study, and the study-
218	level association summaries were meta-analyzed using METAL prior to the lookup of novel BP
219	variants for association with metabolite levels.
220	The same methodology for MR analyses as implemented for CVDs was also adopted to test
221	the effects of metabolites on BP. Causal analyses were restricted to the list of 14 metabolites that
222	overlapped our BP-associations and were known. We used a Bonferroni significance threshold ($P <$
223	0.05/14 = 0.0036), adjusting for the number of metabolites being tested. We also tested for a reverse
224	causal effect of BP on metabolite levels. The IVs for the BP traits were the same as those used for
225	MR with CVDs. For the mvMR analysis of metabolites with BP, we included 3-
226	methylglutarylcarnitine(2) and the three metabolites that shared at least one IV with 3-
227	methylglutarylcarnitine(2) in the mvMR model. A union set of genetic IVs for all the metabolites
228	were used in the mvMR model to simultaneously estimate the effect size of each metabolite on DBP.
229	
230	Colocalization of BP associations with eQTLs. Details of kidney-specific eQTL are provided in
231	Supplementary Information. Using the phenoscanner lookups to prioritize BP regions with eQTLs in
232	GTEx version 7, we performed joint colocalization analysis with the HyPrColoc package in R ³¹
233	(https://github.com/jrs95/hyprcoloc; regional colocalization plots,
234	https://github.com/jrs95/gassocplot). HyPrColoc approximates the COLOC method developed by

Giambartolomei et al.⁶² and extends it to allow colocalization analyses to be performed jointly across many traits simultaneously and pinpoint candidate shared SNV(s). Analyses were restricted to SNVs present in all the datasets used (for GTEx data this was 1 Mb upstream and downstream of the center of the gene probe), data were aligned to the same human genome build 37 and strand, and a similar prior structure as the colocalization analysis with cardiometabolic traits was used (P = 0.0001 and $\gamma = 0.99$).

241

Gene set enrichment analyses. In total, 4,993 GO biological process, 952 GO molecular function,
678 GO cellular component, 53 GTEx, 301 KEGG, 9537 MGI, and 2645 Orphanet gene sets were
used for enrichment analyses (Supplementary Information).

We restricted these analyses to the rare BP-associated SNVs (Supplementary Table 4). For each set of gene sets, the significance of the enrichment of the genetically identified BP genes was assessed as the Fisher's exact test for the over-abundance of BP genes in the designated gene set based on a background of all human protein coding genes or, in the case of the MGI gene sets, a background of all human protein-coding genes with an available knock-out phenotype in the MGI database.

Results were deemed significant if after multiple testing correction for the number of gene sets in the specific set of gene sets the adjusted *P*-value < 0.05. Results were deemed suggestive if the adjusted *P*-value was between 0.05 and 0.1.

254

Functional enrichment using BP-associated variants. To assess enrichment of GWAS variants
associated with the BP traits in regulatory and functional regions in a wide range of cell and tissue
types, we used GWAS Analysis of Regulatory or Functional Information Enrichment with LD
Correction (GARFIELD). The GARFIELD method has been described extensively elsewhere^{76,77}. In
brief, GARFIELD takes a non-parametric approach that requires GWAS summary statistics as input.

260	It performs the	following steps:	(i) LI	D-pruning o	of input	variants;	(ii)	calculation	of the	fold
-----	-----------------	------------------	--------	--------------------	----------	-----------	------	-------------	--------	------

- 261 enrichment of various regulatory/functional elements; and (iii) testing these for statistical
- significance by permutation testing at various GWAS significance levels, accounting for MAF, the
- 263 distance to the nearest transcription start site, and the number of LD proxies of the GWAS variants.
- 264 We used the SNVs from the full UKBB GWAS of BP traits as input to GARFIELD (Supplementary
- 265 Table 4).
- 266

267 Data availability

- 268 Summary association results for all the traits are available for download from:
- 269 https://app.box.com/s/1ev9iakptips70k8t4cm8j347if0ef2u
- and from the CHARGE dbGaP Summary site, (https://www.ncbi.nlm.nih.gov/gap/) accession
- 271 number phs000930.
- 272

274 METHODS-ONLY REFERENCES

- 49. Tobin, M.D., Sheehan, N.A., Scurrah, K.J. & Burton, P.R. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. *Stat. Med.* **24**, 2911-2935 (2005).
- 50. Grove, M.L. et al. Best practices and joint calling of the HumanExome BeadChip: the CHARGE

278 Consortium. *PLoS One* **8**, e68095 (2013).

- Liu, D.J. et al. Meta-analysis of gene-level tests for rare variant association. *Nat. Genet.* 46, 200-204 (2014).
- 281 52. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association 282 scans. *Bioinformatics* **26**, 2190-2191 (2010).
- 53. Fadista, J., Manning, A.K., Florez, J.C. & Groop, L. The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. *Eur. J. Hum. Genet.* **24**, 1202-1205 (2016).
- 54. Flannick, J. et al. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. *Nature* 570, 71-76 (2019).
- 55. Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat. Genet.* **50**, 1505-1513 (2018).
- 56. Mahajan, A. et al. Refining the accuracy of validated target identification through coding variant finemapping in type 2 diabetes. *Nat. Genet.* **50**, 559-571 (2018).
- 57. Yengo, L. et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Hum. Mol. Genet.* **27**, 3641-3649 (2018).
- 293 58. Willer, C.J. et al. Discovery and refinement of loci associated with lipid levels. *Nat. Genet.* **45**, 1274-1283 (2013).
- 59. Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat. Genet.* **42**, 105-116 (2010).
- 297 60. Scott, R.A. et al. An expanded genome-wide association study of type 2 diabetes in Europeans.
 298 *Diabetes* 66, 2888-2902 (2017).
- 299 61. Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat. Genet.* **47**, 1121-1130 (2015).
- 301 62. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies 302 using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
- 303 63. Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat. Genet.* **50**, 524-537 (2018).
- 305 64. van der Harst, P. & Verweij, N. Identification of 64 novel genetic loci provides an expanded view on the 306 genetic architecture of coronary artery disease. *Circ. Res.* **122**, 433-443 (2018).
- 307 65. Burgess, S. et al. Using published data in Mendelian randomization: a blueprint for efficient
- identification of causal risk factors. *Eur. J. Epidemiol.* **30**, 543-552 (2015).
- Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect
 estimation and bias detection through Egger regression. *Int. J. Epidemiol.* 44, 512-525 (2015).
- 67. Verbanck, M., Chen, C.Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat. Genet.* **50**, 693-698 (2018).
- 68. Pierce, B.L., Ahsan, H. & Vanderweele, T.J. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. *Int. J. Epidemiol.* **40**, 740-752 (2011).
- 69. Lawlor, D.A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology. *Int. J. Epidemiol.*45, 1866-1886 (2016).
- 318 70. Sanderson, É., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of multivariable
- Mendelian randomization in the single-sample and two-sample summary data settings. *Int. J. Epidemiol.* **48**, 713-727 (2019).
- 321 71. Di Angelantonio, E. et al. Efficiency and safety of varying the frequency of whole blood donation
- 322 (INTERVAL): a randomised trial of 45 000 donors. *Lancet* **390**, 2360-2371 (2017).

- 323 72. Astle, W.J. et al. The allelic landscape of human blood cell trait variation and links to common complex 324 disease. *Cell* **167**, 1415-1429 e19 (2016).
- 325 73. Day, N. et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective 326 Investigation of Cancer. *Br. J. Cancer* **80 Suppl 1**, 95-103 (1999).
- 327 74. Cancer Genome Atlas Research Network et al. The Cancer Genome Atlas Pan-Cancer analysis 328 project. *Nat. Genet.* **45**, 1113-1120 (2013).
- Bray, N.L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification.
 Nat. Biotechnol. 34, 525-527 (2016).
- 331 76. lotchkova, V. et al. Discovery and refinement of genetic loci associated with cardiometabolic risk using
 332 dense imputation maps. *Nat. Genet.* 48, 1303-1312 (2016).
- Iotchkova, V. et al. GARFIELD classifies disease-relevant genomic features through integration of
 functional annotations with association signals. *Nat. Genet.* **51**, 343-353 (2019).
- T8. Zhu, X. et al. Meta-analysis of correlated traits via summary statistics from GWASs with an application
 in hypertension. *Am. J. Hum. Genet.* 96, 21-36 (2015).
- Newton-Cheh, C. et al. Association of common variants in NPPA and NPPB with circulating natriuretic
 peptides and blood pressure. *Nat. Genet.* 41, 348-53 (2009).
- 339
- 340
- 341
- 342
- 343